Thomas A. Waldmann

Thomas A. Waldmann's AcademicInfluence.com Rankings

Thomas A. Waldmann

Philosophy

#1618

World Rank

#2896

Historical Rank

#636

USA Rank

Logic

#255

World Rank

#533

Historical Rank

#108

USA Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Thomas A. Waldmann Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Thomas A. Waldmann was an American immunologist who has worked on therapeutic monoclonal antibodies to the IL-2 receptor, Interleukin 15 , and Adult T-cell Leukemia . Until the week he died, he was an active distinguished investigator at the Lymphoid Malignancies Branch of the National Cancer Institute.

(See a Problem?)

Thomas A. Waldmann's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Proceedings of the National Academy of Sciences of the United States of America. Annual subject and author indexes. (1990) (2482)
A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells. (1981) (1266)
The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design (2006) (1014)
Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. (2005) (919)
Structure of the human immunoglobulin μ locus: Characterization of embryonic and rearranged J and D genes (1981) (914)
IL-15Rα Recycles and Presents IL-15 In trans to Neighboring Cells (2002) (831)
A monoclonal antibody that appears to recognize the receptor for human T-cell growth factor; partial characterization of the receptor (1982) (783)
Metabolism of immunoglobulins. (1969) (778)
Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics (2012) (766)
The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. (1999) (741)
Molecular cloning and expression of cDNAs for the human interleukin-2 receptor (1984) (701)
Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome. Evidence for a selective defect in soluble antigen recognition. (1985) (698)
Role of suppressor T cells in pathogenesis of common variable hypogammaglobulinaemia. (1974) (633)
Immunoglobulin-gene rearrangements as unique clonal markers in human lymphoid neoplasms. (1983) (614)
A humanized antibody that binds to the interleukin 2 receptor. (1989) (614)
Immunotherapy: past, present and future (2003) (603)
Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. (2006) (599)
Immunoglobulin gene rearrangement and cell surface antigen expression in acute lymphocytic leukemias of T cell and B cell precursor origins. (1983) (596)
Developmental hierarchy of immunoglobulin gene rearrangements in human leukemic pre-B-cells. (1981) (567)
IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T Cells (2004) (553)
Cyclosporin A inhibits T-cell growth factor gene expression at the level of mRNA transcription. (1984) (543)
Dynamic, yet structured: The cell membrane three decades after the Singer–Nicolson model (2003) (496)
Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. (2015) (496)
Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy. (2001) (484)
IL-15: a pleiotropic cytokine with diverse receptor/signaling pathways whose expression is controlled at multiple levels. (1996) (473)
Metabolic properties of IgG subclasses in man. (1970) (468)
Expression of interleukin 2 receptors on activated human B cells (1984) (458)
Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. (2012) (456)
IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells. (2002) (452)
The Sézary syndrome: a malignant proliferation of helper T cells. (1976) (442)
The structure, function, and expression of interleukin-2 receptors on normal and malignant lymphocytes. (1986) (427)
Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. (2000) (425)
The interleukin (IL) 2 receptor beta chain is shared by IL-2 and a cytokine, provisionally designated IL-T, that stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. (1994) (416)
IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice. (2000) (415)
A lymphokine, provisionally designated interleukin T and produced by a human adult T-cell leukemia line, stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. (1994) (407)
Demonstration of a non-Tac peptide that binds interleukin 2: a potential participant in a multichain interleukin 2 receptor complex. (1986) (405)
A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin (1989) (395)
Rearrangement and expression of immunoglobulin genes and expression of Tac antigen in hairy cell leukemia. (1983) (393)
Impaired synthesis of polyclonal (non-paraprotein) immunoglobulins by circulating lymphocytes from patients with multiple myeloma Role of suppressor cells. (1975) (387)
Rearrangements of genes for the antigen receptor on T cells as markers of lineage and clonality in human lymphoid neoplasms. (1985) (376)
Requirement for IRF-1 in the microenvironment supporting development of natural killer cells (1998) (375)
A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. II. Expression of Tac antigen on activated cytotoxic killer T cells, suppressor cells, and on one of two types of helper T cells. (1981) (368)
Human interleukin-2 promotes proliferation of activated B cells via surface receptors similar to those of activated T cells (1984) (364)
Co-adjuvant effects of retinoic acid and IL-15 induce inflammatory immunity to dietary antigens (2011) (360)
The gene SCL is expressed during early hematopoiesis and encodes a differentiation-related DNA-binding motif. (1989) (337)
Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. (2004) (320)
The multi-subunit interleukin-2 receptor. (1989) (318)
Interleukin-15 biology and its therapeutic implications in cancer. (2012) (306)
Clustered arrangement of immunoglobulin λ constant region genes in man (1981) (305)
The role of the gastrointestinal system in "idiopathic hypoproteinemia". (1961) (299)
Protein-losing enteropathy. (1966) (298)
Proliferation of adult T cell leukemia/lymphoma cells is associated with the constitutive activation of JAK/STAT proteins. (1997) (296)
Human immunoglobulin κ light-chain genes are deleted or rearranged in λ-producing B cells (1981) (294)
Superior T memory stem cell persistence supports long-lived T cell memory. (2013) (287)
Serum-alpha-fetoprotein levels in patients with ataxia-telangiectasia. (1972) (286)
THE ROLE OF THE KIDNEY IN THE CATABOLISM OF BENCE JONES PROTEINS AND IMMUNOGLOBULIN FRAGMENTS (1967) (285)
Chromosomal translocation in a human leukemic stem-cell line disrupts the T-cell antigen receptor delta-chain diversity region and results in a previously unreported fusion transcript. (1989) (275)
The renal handling of low molecular weight proteins. II. Disorders of serum protein catabolism in patients with tubular proteinuria, the nephrotic syndrome, or uremia. (1972) (274)
The interleukin-2 receptor. (1991) (274)
Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. (1999) (266)
The mechanism of intestinal uptake and transcellular transport of IgG in the neonatal rat. (1972) (261)
Interleukin 2 (IL-2) augments transcription of the IL-2 receptor gene. (1985) (257)
Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance. (2005) (255)
Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac. (1995) (249)
Blockade of the interleukin-2 receptor by anti-Tac antibody: inhibition of human lymphocyte activation. (1983) (244)
Serum α-Fetoprotein in Patients with Neoplasms of the Gastrointestinal Tract (1975) (242)
Interleukin (IL) 15/IL-T production by the adult T-cell leukemia cell line HuT-102 is associated with a human T-cell lymphotrophic virus type I region /IL-15 fusion message that lacks many upstream AUGs that normally attenuates IL-15 mRNA translation. (1996) (230)
Cellular localization of alpha‐fetoprotein and human chorionic gonadotropin in germ cell tumors of the testis using an indirect immunoperoxidase technique. A new approach to classification utilizing tumor markers (1977) (227)
Loss of suppressor T cells in adult NZB/NZW mice (1976) (223)
Disorders of suppressor immunoregulatory cells in the pathogenesis of immunodeficiency and autoimmunity. (1978) (222)
Cytokines in the Treatment of Cancer. (2019) (220)
Regulation of interleukin 2 receptor expression: effects of phorbol diester, phospholipase C, and reexposure to lectin or antigen. (1984) (212)
The p75 peptide is the receptor for interleukin 2 expressed on large granular lymphocytes and is responsible for the interleukin 2 activation of these cells. (1987) (211)
The IL-2/IL-2 receptor system: a target for rational immune intervention. (1993) (210)
Lymphoid blast crises of chronic myelogenous leukemia represent stages in the development of B-cell precursors. (1983) (208)
Generation of secretable and nonsecretable interleukin 15 isoforms through alternate usage of signal peptides. (1997) (206)
Immunodeficiency disease and malignancy. Various immunologic deficiencies of man and the role of immune processes in the control of malignant disease. (1972) (204)
The use of a radioimmunoassay for alpha‐fetoprotein in the diagnosis of malignancy (1974) (204)
Interleukin-2, interleukin-15, and their receptors. (1998) (202)
Functional and phenotypic comparison of human T cell leukemia/lymphoma virus positive adult T cell leukemia with human T cell leukemia/lymphoma virus negative Sézary leukemia, and their distinction using anti-Tac. Monoclonal antibody identifying the human receptor for T cell growth factor. (1984) (202)
Characterization of the human receptor for T-cell growth factor. (1983) (200)
Preassociation of IL-15 with IL-15Rα-IgG1-Fc Enhances Its Activity on Proliferation of NK and CD8+/CD44high T Cells and Its Antitumor Action1 (2008) (195)
Coadministration of HIV vaccine vectors with vaccinia viruses expressing IL-15 but not IL-2 induces long-lasting cellular immunity (2003) (190)
Bismuth-212-labeled anti-Tac monoclonal antibody: alpha-particle-emitting radionuclides as modalities for radioimmunotherapy. (1986) (187)
Human γ-chain genes are rearranged in leukaemic T cells and map to the short arm of chromosome 7 (1985) (187)
Human immunoglobulin D segments encoded in tandem multigenic families (1981) (187)
Separation of human blood monocytes and lymphocytes on a continuous Percoll gradient. (1980) (186)
Coimmunization with an Optimized IL-15 Plasmid Results in Enhanced Function and Longevity of CD8 T Cells That Are Partially Independent of CD4 T Cell Help3 (2005) (184)
The 5' untranslated region, signal peptide, and the coding sequence of the carboxyl terminus of IL-15 participate in its multifaceted translational control. (1998) (183)
Human T cell lymphotropic virus type I Tax protein trans-activates interleukin 15 gene transcription through an NF-κB site (1998) (179)
Simultaneous Blockade of Multiple Immune System Inhibitory Checkpoints Enhances Antitumor Activity Mediated by Interleukin-15 in a Murine Metastatic Colon Carcinoma Model (2010) (179)
METABOLISM OF HUMAN GAMMA MACROGLOBULINS. (1964) (178)
T-lymphocyte interleukin 2-dependent tyrosine protein kinase signal transduction involves the activation of p56lck. (1991) (178)
The human interleukin-2 receptor: normal and abnormal expression in T cells and in leukemias induced by the human T-lymphotropic retroviruses. (1986) (178)
Cytokines in Cancer Immunotherapy. (2018) (177)
Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. (1994) (177)
The suppressor-cell network in cancer (first of two parts). (1978) (176)
Intestinal lymphangiectasia: a protein-losing enteropathy with hypogammaglobulinemia, lymphocytopenia and impaired homograft rejection. (1967) (174)
The Wiskott-Aldrich syndrome. A disorder with a possible defect in antigen processing or recognition. (1968) (172)
Augmented T cell growth factor receptor expression in HTLV-1-infected human leukemic T cells. (1984) (171)
Nature of the bifunctional chelating agent used for radioimmunotherapy with yttrium-90 monoclonal antibodies: critical factors in determining in vivo survival and organ toxicity. (1989) (170)
X-linked hypogammaglobulinemia and isolated growth hormone deficiency. (1980) (170)
A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation. (1991) (168)
Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. (2009) (168)
Expression of functional IL 2 receptors by lipopolysaccharide and interferon-gamma stimulated human monocytes. (1987) (167)
Responses in refractory hairy cell leukemia to a recombinant immunotoxin. (1999) (167)
CD7+, CD4-, CD8- acute leukemia: a syndrome of malignant pluripotent lymphohematopoietic cells. (1989) (166)
Cholesterol-dependent clustering of IL-2Ralpha and its colocalization with HLA and CD48 on T lymphoma cells suggest their functional association with lipid rafts. (2000) (164)
Therapy of patients with human T-cell lymphotrophic virus I-induced adult T-cell leukemia with anti-Tac, a monoclonal antibody to the receptor for interleukin-2. (1988) (164)
Allergic gastroenteropathy. A cause of excessive gastrointestinal protein loss. (1967) (161)
The value of serum tumor markers in the staging and prognosis of germ cell tumors of the testis. (1977) (159)
Monoclonal-antibody-mediated apoptosis in adult T-cell leukaemia (1990) (156)
A Pilot Study of CTLA-4 Blockade after Cancer Vaccine Failure in Patients with Advanced Malignancy (2007) (156)
The role of the kidney in the metabolism of plasma proteins. (1974) (155)
Rapid Progression of Adult T-Cell Leukemia-Lymphoma after PD-1 Inhibitor Therapy. (2018) (154)
Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. (2011) (153)
Polyclonal B-cell activators in the study of the regulation of immunoglobulin synthesis in the human system. (1982) (152)
Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia. (2002) (152)
Characterization of a suppressor-cell leukemia. Evidence for the requirement of an interaction of two T cells in the development of human suppressor effector cells. (1978) (152)
The IL-15/IL-15Rα on cell surfaces enables sustained IL-15 activity and contributes to the long survival of CD8 memory T cells (2007) (152)
IL-15 as a mediator of CD4+ help for CD8+ T cell longevity and avoidance of TRAIL-mediated apoptosis (2008) (151)
The Shared and Contrasting Roles of IL2 and IL15 in the Life and Death of Normal and Neoplastic Lymphocytes: Implications for Cancer Therapy (2015) (150)
Pheochromocytoma: current concepts of diagnosis and treatment. Combined clinical staff conference at the National Institutes of Health. (1966) (149)
SYSTEMIC CAPILLARY LEAK SYNDROME AND MONOCLONAL IgG GAMMOPATHY: Studies in a Sixth Patient and a Review of the Literature (1977) (149)
Accelerated breakdown of immunoglobulin G (IgG) in myotonic dystrophy: a hereditary error of immunoglobulin catabolism. (1966) (148)
GASTROINTESTINAL PROTEIN LOSS DEMONSTRATED BY 51Cr-LABELLED ALBUMIN (1961) (148)
NIH conference. T-cell lymphoproliferative syndrome associated with human T-cell leukemia/lymphoma virus. (1984) (147)
HUMORAL SYNDROMES ASSOCIATED WITH NONENDOCRINE TUMORS. (1964) (147)
Preassembly of interleukin 2 (IL-2) receptor subunits on resting Kit 225 K6 T cells and their modulation by IL-2, IL-7, and IL-15: a fluorescence resonance energy transfer study. (1997) (146)
Only high-affinity receptors for interleukin 2 mediate internalization of ligand. (1986) (146)
The role of interleukin-15 in inflammation and immune responses to infection: implications for its therapeutic use. (2012) (145)
APO-1-induced apoptosis of leukemia cells from patients with adult T-cell leukemia. (1993) (145)
Identification of a novel receptor/signal transduction pathway for IL‐15/T in mast cells (1996) (143)
Lymphatic drainage imaging of breast cancer in mice by micro-magnetic resonance lymphangiography using a nano-size paramagnetic contrast agent. (2004) (142)
The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia. (1993) (142)
Recruitment of SH2-containing protein tyrosine phosphatase SHP-1 to the interleukin 2 receptor; loss of SHP-1 expression in human T-lymphotropic virus type I-transformed T cells. (1998) (141)
The use of antibodies against the IL-2 receptor in transplantation. (1998) (140)
Familial hypercatabolic hypoproteinemia caused by deficiency of the neonatal Fc receptor, FcRn, due to a mutant beta2-microglobulin gene. (2006) (136)
Interleukin-15 combined with an anti-CD40 antibody provides enhanced therapeutic efficacy for murine models of colon cancer (2009) (134)
The arrangement of immunoglobulin and T cell receptor genes in human lymphoproliferative disorders. (1987) (133)
Evidence for a defect in "switch" T cells in patients with immunodeficiency and hyperimmunoglobulinemia M. (1986) (132)
Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence. (2006) (132)
Suppressor cells in the regulation of the immune response. (1977) (132)
A vital role for IL-2 trans-presentation in DC-mediated T cell activation in humans as revealed by daclizumab therapy (2011) (131)
Serum alpha fetoprotein and human chorionic gonadotropin in the diagnosis and management of nonseminomatous germ-cell testicular cancer. (1976) (131)
First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia. (2019) (131)
Defective lymphocyte transformation and delayed hypersensitivity in Wiskott-Aldrich syndrome. (1970) (131)
Immunoglobulin E in immunologic deficiency diseases. II. Serum IgE concentration of patients with acquired hypogammaglobulinemia, thymoma and hypogammaglobulinemia, myotonic dystrophy, intestinal lymphangiectasia and Wiskott-Aldrich syndrome. (1972) (131)
Protein-losing gastroenteropathy in congestive heart-failure. (1961) (130)
METABOLISM OF BENCE JONES PROTEINS. (1964) (128)
IL-15/IL-15Rα-mediated avidity maturation of memory CD8 + T cells (2004) (128)
Normal human B cells display ordered light chain gene rearrangements and deletions (1982) (127)
Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report (2019) (127)
Anti-Tac (daclizumab, Zenapax) in the Treatment of Leukemia, Autoimmune Diseases, and in the Prevention of Allograft Rejection: A 25-Year Personal Odyssey (2007) (127)
Interleukin-2 activity can be fine tuned with engineered receptor signaling clamps. (2015) (126)
Cytokine induction in HTLV‐I associated myelopathy and adult T‐cell leukemia: Alternate molecular mechanisms underlying retroviral pathogenesis (1991) (126)
Advances in interleukin 2 receptor targeted treatment (2000) (125)
IL-15 induces the expression of chemokines and their receptors in T lymphocytes. (1999) (125)
Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. (2003) (124)
Clinical and experimental metabolism of normal 6.6s gamma-globulin in normal subjects and in patients with macroglobulinemia and multiple myeloma. (1963) (124)
Antibody-mediated blockade of IL-15 reverses the autoimmune intestinal damage in transgenic mice that overexpress IL-15 in enterocytes (2009) (123)
The association of polycythemia with a cerebellar hemangioblastoma. The production of an erythropoiesis stimulating factor by the tumor. (1961) (123)
The role of the gastrointestinal tract in plasma protein metabolism. Studies with 51Cr-albumin. (1969) (123)
IL-2 and IL-15 receptor alpha-subunits are coexpressed in a supramolecular receptor cluster in lipid rafts of T cells. (2004) (121)
Gain-of-function CCR4 mutations in adult T cell leukemia/lymphoma (2014) (121)
Variable amplification of immunoglobulin λ light-chain genes in human populations (1983) (119)
Characterization of common variable immunodeficiency: identification of a subset of patients with distinctive immunophenotypic and clinical features. (1990) (118)
The multichain interleukin-2 receptor: a target for immunotherapy. (1988) (117)
A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors (2017) (116)
Renal handling of low molecular weight proteins. I. L-Chain metabolism in experimental renal disease. (1971) (115)
Testicular germ-cell neoplasms: recent advances in diagnosis and therapy. (1979) (113)
Discordance of human chorionic gonadotropin and alpha‐fetoprotein in testicular teratocarcinomas (1973) (113)
Transient and persistent effects of IL-15 on lymphocyte homeostasis in nonhuman primates. (2010) (112)
SYSTEMIC LYMPHATIC ABNORMALITIES ASSOCIATED WITH GASTROINTESTINAL PROTEIN LOSS SECONDARY TO INTESTINAL LYMPHANGIECTASIA. (1963) (111)
The Long Signal Peptide Isoform and Its Alternative Processing Direct the Intracellular Trafficking of Interleukin-15* (2000) (107)
Disorders of the JAK/STAT Pathway in T Cell Lymphoma Pathogenesis: Implications for Immunotherapy. (2017) (106)
Micro-magnetic resonance lymphangiography in mice using a novel dendrimer-based magnetic resonance imaging contrast agent. (2003) (106)
Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the alpha-emitting radionuclide, bismuth 213. (2002) (106)
Detection of sequences homologous to human retroviral DNA in multiple sclerosis by gene amplification. (1989) (106)
The mechanism of appearance of immunoglobulin A in nasal secretions in man. (1967) (105)
Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts (2003) (104)
Immunoglobulin metabolism in ataxia telangiectasia. (1968) (104)
Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H. (2003) (104)
α-Fetoprotein in Nonneoplastic Hepatic Disorders (1975) (103)
Contribution of a p75 interleukin 2 binding peptide to a high-affinity interleukin 2 receptor complex. (1987) (103)
Soluble suppressor supernatants elaborated by concanavalin A-activated human mononuclear cells. I. Characterization of a soluble suppressor T cell proliferation. (1981) (103)
The IL-2/IL-15 Receptor Systems: Targets for Immunotherapy (2002) (103)
Onset of natural killer cell lymphomas in transgenic mice carrying a truncated HMGI-C gene by the chronic stimulation of the IL-2 and IL-15 pathway (2001) (103)
ITK and IL-15 support two distinct subsets of CD8+ T cells (2006) (102)
Effective cancer therapy through immunomodulation. (2006) (102)
Comparison of dendrimer‐based macromolecular contrast agents for dynamic micro‐magnetic resonance lymphangiography (2003) (100)
Hypercatabolism of IgG, IgA, IgM, and albumin in the Wiskott-Aldrich syndrome. A unique disorder of serum protein metabolism. (1971) (100)
A Double-masked, Randomized Study to Investigate the Safety and Efficacy of Daclizumab to Treat the Ocular Complications Related to Behçet's Disease (2007) (99)
Frequent STAT5B mutations in γδ hepatosplenic T-cell lymphomas (2014) (98)
miR-155 augments CD8+ T-cell antitumor activity in lymphoreplete hosts by enhancing responsiveness to homeostatic γc cytokines (2014) (97)
Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model (2012) (96)
Colocalization and nonrandom distribution of Kv1.3 potassium channels and CD3 molecules in the plasma membrane of human T lymphocytes (2003) (96)
Primary amyloidosis. Clinical, immunochemical and immunoglobulin metabolism. Studies in fifteen patients. (1969) (96)
Novel T-lymphocyte population in combined immunodeficiency with features of graft-versus-host disease. (1989) (96)
Immunoglobulin and T-cell receptor gene rearrangement and expression in human lymphoid leukemia cells at different stages of maturation. (1986) (96)
Ataxia-telangiectasis: a multisystem hereditary disease with immunodeficiency, impaired organ maturation, x-ray hypersensitivity, and a high incidence of neoplasia. (1983) (95)
The role of suppressor cells in the pathogenesis of common variable hypogammaglobulinemia and the immunodeficiency associated with myeloma. (1976) (95)
Protection against simian/human immunodeficiency virus (SHIV) 89.6P in macaques after coimmunization with SHIV antigen and IL-15 plasmid (2007) (95)
Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1. (1997) (95)
Similarities and differences in 111In- and 90Y-labeled 1B4M-DTPA antiTac monoclonal antibody distribution. (1999) (94)
Metabolism of human immunoglobulin D (IgD). (1966) (94)
Survival adjustment of mature dendritic cells by IL-15. (2005) (94)
Enhanced chromatid damage in blood lymphocytes after G2 phase x irradiation, a marker of the ataxia-telangiectasia gene. (1990) (93)
Activation of human monocytes induces differential resistance to apoptosis with rapid down regulation of caspase-8/FLICE. (1998) (92)
Ecto-5'-nucleotidase activity in T and B lymphocytes from normal subjects and patients with congenital X-linked agammaglobulinemia. (1979) (92)
Elevated levels of soluble interleukin-2 receptors in multiple sclerosis. (1988) (92)
Phenotypic knockout of the high-affinity human interleukin 2 receptor by intracellular single-chain antibodies against the alpha subunit of the receptor. (1995) (91)
Notch signaling contributes to proliferation and tumor formation of human T-cell leukemia virus type 1–associated adult T-cell leukemia (2010) (91)
Human T Cell Lymphotropic Virus Type I Tax Activates IL-15Rα Gene Expression Through an NF-κB Site (2001) (91)
Disorders of immunoglobulin metabolism. (1969) (90)
Suppressor cells in neoplastic disease. (1978) (89)
Immunoglobulin E in immunologic deficiency diseases. I. Relation of IgE and IgA to respiratory tract disease in isolated IgE deficiency, IgA deficiency, and ataxia telangiectasia. (1972) (88)
alpha-fetoprotein in noneoplastic hepatic disorders. (1975) (88)
Primary immunodeficiency diseases. Report prepared for the WHO by a scientific group on immunodeficiency. (1983) (86)
Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma (2007) (86)
Flow cytometric resonance energy transfer measurements support the association of a 95-kDa peptide termed T27 with the 55-kDa Tac peptide. (1987) (86)
Involvement of IL-15 in the pathogenesis of human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis: implications for therapy with a monoclonal antibody directed to the IL-2/15R beta receptor. (1999) (86)
Life Span of Red Blood Cell (1959) (86)
IL-15 enhanced antibody-dependent cellular cytotoxicity mediated by NK cells and macrophages (2018) (85)
Familial hypercatabolic hypoproteinemia. A disorder of endogenous catabolism of albumin and immunoglobulin. (1990) (85)
GPI-microdomains (membrane rafts) and signaling of the multi-chain interleukin-2 receptor in human lymphoma/leukemia T cell lines. (2002) (85)
IL-15 in the Combination Immunotherapy of Cancer (2020) (83)
FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma. (2011) (82)
Pseudomonas exotoxin-anti-TAC. Cell-specific immunotoxin active against cells expressing the human T cell growth factor receptor. (1984) (82)
trans activation of granulocyte-macrophage colony-stimulating factor and the interleukin-2 receptor in transgenic mice carrying the human T-lymphotropic virus type 1 tax gene (1989) (82)
IL-15 administered by continuous infusion to rhesus macaques induces massive expansion of CD8+ T effector memory population in peripheral blood. (2011) (82)
The biology of IL-15: implications for cancer therapy and the treatment of autoimmune disorders. (2013) (81)
Application of a Macromolecular Contrast Agent for Detection of Alterations of Tumor Vessel Permeability Induced by Radiation (2004) (81)
The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia (1993) (81)
The human receptor for T-cell growth factor. Evidence for variable post-translational processing, phosphorylation, sulfation, and the ability of precursor forms of the receptor to bind T-cell growth factor. (1985) (80)
Serum alpha-fetoprotein in patients with neoplasms of the gastrointestinal tract. (1975) (80)
The metabolism of IgE. Studies in normal individuals and in a patient with IgE myeloma. (1976) (79)
Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD2 monoclonal antibody, MEDI-507. (2003) (78)
Measurement of gastrointestinal protein loss using ceruloplasmin labeled with copper. (1967) (77)
CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM/TSP. (2011) (77)
The recombinant immunotoxin anti-Tac(Fv)-Pseudomonas exotoxin 40 is cytotoxic toward peripheral blood malignant cells from patients with adult T-cell leukemia. (1990) (77)
Disorders of B cells and helper T cells in the pathogenesis of the immunoglobulin deficiency of patients with ataxia telangiectasia. (1983) (76)
High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis. (2008) (76)
Changes in IgA and IgG concentrations in nasal secretions prior to the appearance of antibody during viral respiratory infection in man. (1970) (76)
The contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for the immunotherapy of rheumatological diseases (2002) (76)
Human B cell activation in vitro: augmentation and suppression by monocytes of the immunoglobulin production induced by various B cell stimulants. (1981) (76)
Multichain interleukin-2 receptor: a target for immunotherapy in lymphoma. (1989) (76)
Impaired lymphocyte transformation in intestinal lymphangiectasia: evidence for at least two functionally distinct lymphocyte populations in man. (1972) (75)
Humanized antibodies against the alpha-chain of the IL-2 receptor and against the beta-chain shared by the IL-2 and IL-15 receptors in a monkey uveitis model of autoimmune diseases. (1997) (74)
Clustered arrangement of immunoglobulin lambda constant region genes in man. (1981) (74)
p53 stabilization and functional impairment in the absence of genetic mutation or the alteration of the p14(ARF)-MDM2 loop in ex vivo and cultured adult T-cell leukemia/lymphoma cells. (2000) (73)
ELEVATED γ-GLOBULIN AND INCREASED ANTIBODY PRODUCTION IN MICE INFECTED WITH LACTIC DEHYDROGENASE VIRUS (1966) (73)
Radioimmunotherapy of Nude Mice Bearing a Human Interleukin 2 Receptor α-expressing Lymphoma Utilizing the α-emitting Radionuclide-conjugated Monoclonal Antibody 212Bi-anti-Tac (1994) (72)
IL15 and T-cell Stemness in T-cell-Based Cancer Immunotherapy. (2015) (72)
Gene expression profiling of ATL patients: compilation of disease-related genes and evidence for TCF4 involvement in BIRC5 gene expression and cell viability. (2009) (72)
The suppressor-cell network in cancer (second of two parts). (1978) (71)
The Combination of Zidovudine and Interferon AIpha-2B in the Treatment of Adult T-Cell Leukemia/Lymphoma (2001) (71)
Tricuspid regurgitation. A newly recognized cause of protein-losing enteropathy, lymphocytopenia and immunologic deficiency. (1968) (71)
IL-15 plays a major role in the persistence of Tax-specific CD8 cells in HAM/TSP patients (2001) (71)
NIH conference. Molecular genetic analysis of human lymphoid neoplasms. Immunoglobulin genes and the c-myc oncogene. (1985) (70)
The pharmacokinetic characteristics of glycolated humanized anti-Tac Fabs are determined by their isoelectric points. (1999) (69)
STUDIES ON THE METABOLISM OF THE SERUM PROTEINS AND LIPIDS IN A PATIENT WITH ANALBUMINEMIA. (1964) (69)
Phase 1 trial of IL-15 trans presentation blockade using humanized Mikβ1 mAb in patients with T-cell large granular lymphocytic leukemia. (2013) (69)
Human T cell lymphotropic virus type I Tax protein trans-activates interleukin 15 gene transcription through an NF-kappaB site. (1998) (68)
Activating Fc Receptors Are Required for Antitumor Efficacy of the Antibodies Directed toward CD25 in a Murine Model of Adult T-Cell Leukemia (2004) (68)
Defect in IgA secretion and in IgA specific suppressor cells in patients with selective IgA deficiency. (1976) (68)
Reduction in HTLV‐I proviral load and spontaneous lymphoproliferation in HTLV‐I–associated myelopathy/tropical spastic paraparesis patients treated with humanized anti‐tac (1998) (68)
Type I and II insulin-like growth factor receptors on human phytohemagglutinin-activated T lymphocytes. (1987) (68)
IDIOPATHIC HYPOALBUMINEMIAS: CLINICAL STAFF CONFERENCE AT THE NATIONAL INSTITUTES OF HEALTH (1959) (68)
Preclinical and phase I clinical trial of blockade of IL-15 using Mikbeta1 monoclonal antibody in T cell large granular lymphocyte leukemia. (2006) (67)
IGG (7 S GAMMA GLOBULIN) METABOLISM IN HYPOGAMMAGLOBULINEMIA: STUDIES IN PATIENTS WITH DEFECTIVE GAMMA GLOBULIN SYNTHESIS, GASTROINTESTINAL PROTEIN LOSS, OR BOTH. (1965) (67)
Rapid Progression of Adult T-Cell Leukemia/Lymphoma as Tumor Infiltrating Treg Cells after PD-1 Blockade. (2019) (66)
Association of intercellular adhesion molecule 1 with the multichain high-affinity interleukin 2 receptor. (1990) (66)
Prolongation of primate renal allograft survival by anti-Tac, an anti-human IL-2 receptor monoclonal antibody. (1989) (66)
Soluble suppressor supernatants elaborated by concanavalin A-activated human mononuclear cells. II. Characterization of a soluble suppressor of B cell immunoglobulin production. (1981) (65)
Regulation of IFN Regulatory Factor 4 Expression in Human T Cell Leukemia Virus-I-Transformed T Cells1 (2002) (65)
Primary immunodeficiency diseases. Report of a World Health Organization scientific group. (1986) (65)
B cell, helper T cell, and suppressor T cell abnormalities contribute to disordered immunoglobulin synthesis in patients following bone marrow transplantation. (1982) (64)
Targeting the interleukin-15/interleukin-15 receptor system in inflammatory autoimmune diseases (2004) (64)
Nanometer-scale organization of the alpha subunits of the receptors for IL2 and IL15 in human T lymphoma cells (2008) (63)
IL-15/IL-15Ralpha-mediated avidity maturation of memory CD8+ T cells. (2004) (63)
Prevention of autoimmunity in experimental lupus erythematosus by soluble immune response suppressor. (1977) (63)
Gene regulation and suppression of type I interferon signaling by STAT3 in diffuse large B cell lymphoma (2018) (62)
Targeting the HTLV-I-Regulated BATF3/IRF4 Transcriptional Network in Adult T Cell Leukemia/Lymphoma. (2018) (62)
Induction of the IL-9 gene by HTLV-I Tax stimulates the spontaneous proliferation of primary adult T-cell leukemia cells by a paracrine mechanism. (2008) (62)
IL15 Infusion of Cancer Patients Expands the Subpopulation of Cytotoxic CD56bright NK Cells and Increases NK-Cell Cytokine Release Capabilities (2017) (61)
A MALIGNANT PROLIFERATION OF HELPER T CELLS (1976) (60)
Phytohemagglutinin as a skin test for the evaluation of cellular immune competence in man. (1973) (60)
IL15 by Continuous Intravenous Infusion to Adult Patients with Solid Tumors in a Phase I Trial Induced Dramatic NK-Cell Subset Expansion (2019) (60)
Deletional rearrangement in the human T-cell receptor alpha-chain locus. (1987) (60)
Vaccinia Virus-Based Multivalent H5N1 Avian Influenza Vaccines Adjuvanted with IL-15 Confer Sterile Cross-Clade Protection in Mice1 (2009) (60)
IgE in immunodeficiency. (1972) (60)
Interleukin 2 (IL2) PE40 is cytotoxic to cells displaying either the p55 or p70 subunit of the IL2 receptor. (1988) (59)
Interleukin-15 in the treatment of cancer (2014) (59)
Relationship of serum alpha-fetoprotein to the severity and duration of illness in patients with viral hepatitis. (1975) (59)
The role of the gastrointestinal system in "idiopathic hypoproteinemia". (1968) (59)
IL-15 in the life and death of lymphocytes: immunotherapeutic implications. (2003) (59)
Renal cysts, erythropoietin and polycythemia. (1963) (59)
Increased serum soluble IL-15Rα levels in T-cell large granular lymphocyte leukemia. (2012) (58)
Interleukin-15 (dys)regulation of lymphoid homeostasis: Implications for therapy of autoimmunity and cancer (2019) (58)
Heterogeneity of lymphocyte subpopulations in severe combined immunodeficiency. Evidence against a stem cell defect. (1976) (58)
Anaphylactic reactions to IgA: a difficult transfusion problem. (1970) (58)
Human immunoglobulin kappa light-chain genes are deleted or rearranged in lambda-producing B cells. (1981) (57)
Detection of lymph node involvement in hematologic malignancies using micromagnetic resonance lymphangiography with a gadolinum-labeled dendrimer nanoparticle. (2005) (56)
Regulation of normal B-cell differentiation and malignant B-cell survival by OCT2 (2016) (56)
Serum α-Fetoprotein in Patients with Massive Hepatic Necrosis (1977) (56)
Hypogammaglobulinemia in experimental myeloma: the role of suppressor factors from mononuclear phagocytes. (1977) (55)
EBV-Related Lymphoproliferative Disease Complicating Therapy with the Anti-CD2 Monoclonal Antibody, Siplizumab, in Patients with T-Cell Malignancies (2009) (55)
Human T cell lymphotropic virus type I Tax activates IL-15R alpha gene expression through an NF-kappa B site. (2001) (55)
Differences of biodistribution, pharmacokinetics, and tumor targeting between interleukins 2 and 15. (2000) (55)
Juxtaposition of the T-cell receptor alpha-chain locus (14q11) and a region (14q32) of potential importance in leukemogenesis by a 14;14 translocation in a patient with T-cell chronic lymphocytic leukemia and ataxia-telangiectasia. (1988) (55)
Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma. (2014) (55)
Evolution of a lymphoma with helper T cell characteristics in Sézary syndrome. (1978) (54)
Tofacitinib, a Janus Kinase Inhibitor Demonstrates Efficacy in an IL-15 Transgenic Mouse Model that Recapitulates Pathologic Manifestations of Celiac Disease (2013) (54)
Selective IgA deficiency associated with total villous atrophy of the small intestine and an organ-specific anti-epithelial cell antibody. (1978) (54)
ABNORMALITIES OF ALBUMIN METABOLISM IN PATIENTS WITH HYPOGAMMAGLOBULINEMIA. (1962) (54)
Chimeric antigen receptor modified T cells that target chemokine receptor CCR4 as a therapeutic modality for T‐cell malignancies (2017) (54)
Direct measurement of the rates of synthesis of plasma proteins in control subjects and patients with gastrointestinal protein loss. (1968) (54)
Highly Persistent and Effective Prime/Boost Regimens against Tuberculosis That Use a Multivalent Modified Vaccine Virus Ankara-Based Tuberculosis Vaccine with Interleukin-15 as a Molecular Adjuvant (2010) (54)
Insulin-dependent diabetes induced by pancreatic beta cell expression of IL-15 and IL-15Rα (2013) (54)
Life span of red blood cell. (1959) (53)
Cytokine receptor signaling is required for the survival of ALK− anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations (2017) (52)
Effects of the tyrosine‐kinase inhibitor geldanamycin on ligand‐induced HER‐2/NEU activation, receptor expression and proliferation of HER‐2‐positive malignant cell lines (1997) (52)
Viral Activation of Interleukin-15 (IL-15): Characterization of a Virus-Inducible Element in the IL-15 Promoter Region (2002) (52)
Immunoconjugates of geldanamycin and anti-HER2 monoclonal antibodies: antiproliferative activity on human breast carcinoma cell lines. (2000) (51)
Effective Treatment of Established Human Breast Tumor Xenografts in Immunodeficient Mice with a Single Dose of the α-Emitting Radioisotope Astatine-211 Conjugated to Anti-HER2/neu Diabodies (2008) (51)
IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction. (2000) (51)
Elevated serum-soluble interleukin-2 receptor levels in patients with anaplastic large cell lymphoma. (2004) (50)
Serum immunoglobulin E levels in patients with neoplastic disease. (1974) (50)
A biophysical approach to IL-2 and IL-15 receptor function: localization, conformation and interactions. (2008) (50)
Selective targeting of JAK/STAT signaling is potentiated by Bcl-xL blockade in IL-2-dependent adult T-cell leukemia (2015) (50)
Cytotoxic activities of recombinant immunotoxins composed of Pseudomonas toxin or diphtheria toxin toward lymphocytes from patients with adult T-cell leukemia. (1993) (50)
The interleukin 2 receptor (IL-2R): the IL-2R alpha subunit alters the function of the IL-2R beta subunit to enhance IL-2 binding and signaling by mechanisms that do not require binding of IL-2 to IL-2R alpha subunit. (1992) (49)
The effect of hydrocortisone on immunoglobulin metabolism. (1970) (49)
Radionuclide-conjugated monoclonal antibodies: a synthesis of immunology, inorganic chemistry and nuclear science (1986) (49)
Polycythemia Secondary to a Pheochromocytoma with Production of an Erythropoiesis Stimulating Factor by the Tumor (1961) (49)
Development of antibodies and chimeric molecules for cancer immunotherapy. (2006) (49)
Abnormal cytokine expression in Sézary and adult T-cell leukemia cells correlates with the functional diversity between these T-cell malignancies. (1994) (49)
The origin of salivary IgA. (1970) (49)
Comparative cellular catabolism and retention of astatine-, bismuth-, and lead-radiolabeled internalizing monoclonal antibody. (2001) (49)
Effective treatment of a murine model of adult T-cell leukemia using depsipeptide and its combination with unmodified daclizumab directed toward CD25. (2009) (49)
Corticosteroid-responsive intestinal lymphangiectasia secondary to an inflammatory process. (1979) (48)
IL-15 in the life and death of lymphocytes: Implications for cancer therapy and vaccine design (2007) (48)
IL-15 adjuvanted multivalent vaccinia-based universal influenza vaccine requires CD4+ T cells for heterosubtypic protection (2014) (47)
Lateral diffusion measurements give evidence for association of the Tac peptide of the IL-2 receptor with the T27 peptide in the plasma membrane of HUT-102-B2 T cells. (1988) (47)
Immune receptors: targets for therapy of leukemia/lymphoma, autoimmune diseases and for the prevention of allograft rejection. (1992) (46)
Interleukin-15 and its receptor augment dendritic cell vaccination against the neu oncogene through the induction of antibodies partially independent of CD4 help. (2010) (46)
90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin’s lymphoma (2015) (46)
Factors controlling erythropoiesis in birds. (1966) (46)
Interleukin 2 receptor (Tac antigen) expression in HTLV-I-associated adult T-cell leukemia. (1985) (46)
Polyclonal Activation of Human B Lymphocytes by Nocardia Water Soluble Mitogen (NWSM) (1979) (46)
Complete Remissions of Adult T-cell Leukemia with Anti-CD25 Recombinant Immunotoxin LMB-2 and Chemotherapy to Block Immunogenicity (2015) (46)
Cellular localization of alpha-fetoprotein and human chorionic gonadotropin in germ cell tumors of the testis using and indirect immunoperoxidase technique. (1977) (46)
Autocrine/paracrine cytokine stimulation of leukemic cell proliferation in smoldering and chronic adult T-cell leukemia. (2010) (46)
THE ERYTHROPOIESIS‐STIMULATING FACTORS PRODUCED BY TUMORS (1968) (45)
Distinct pathways involving the FK506-binding proteins 12 and 12.6 underlie IL-2-versus IL-15-mediated proliferation of T cells (2003) (45)
Humanized Mik beta 1, a humanized antibody to the IL-2 receptor beta-chain that acts synergistically with humanized anti-TAC. (1993) (45)
Monoclonal anti-IL-2 receptor antibody in primate renal transplantation. (1987) (45)
Protein-losing gastroenteropathy and malabsorption associated with factitious diarrhea. (1968) (45)
Pharmacokinetics and bioactivity of 1,4,7,10-tetra-azacylododecane off',N'',N'''-tetraacetic acid (DOTA)-bismuth-conjugated anti-Tac antibody for alpha-emitter (212Bi) therapy. (1993) (44)
Comparative assessment of virulence of recombinant vaccinia viruses expressing IL-2 and IL-15 in immunodeficient mice (2001) (44)
Leukemia of non-T lineage natural killer cells (1988) (43)
Herceptin-Geldanamycin Immunoconjugates (2004) (43)
Clustering of Class I HLA Oligomers with CD8 and TCR: Three-Dimensional Models Based on Fluorescence Resonance Energy Transfer and Crystallographic Data1 (2001) (43)
Constrictive pericarditis, intestinal lymphangiectasia, and reversible immunologic deficiency. (1975) (43)
Radioimmunotherapy of A431 xenografted mice with pretargeted B3 antibody-streptavidin and (90)Y-labeled 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-biotin. (2002) (43)
Cellular origin of hairy cell leukemia: malignant B cells that express receptors for T cell growth factor. (1984) (43)
Development of Smallpox Vaccine Candidates with Integrated Interleukin-15 That Demonstrate Superior Immunogenicity, Efficacy, and Safety in Mice (2007) (42)
Augmented IL-15Rα Expression by CD40 Activation Is Critical in Synergistic CD8 T Cell-Mediated Antitumor Activity of Anti-CD40 Antibody with IL-15 in TRAMP-C2 Tumors in Mice (2012) (42)
Phorbol diester induces expression of Tac antigen on human acute T lymphocytic leukemic cells. (1984) (42)
Human chorionic gonadotropin and alphafetoprotein in the staging of nonseminomatous testicular cancer (1981) (41)
MTS dye based colorimetric CTLL-2 cell proliferation assay for product release and stability monitoring of interleukin-15: assay qualification, standardization and statistical analysis. (2009) (41)
In vitro generation of antigen-specific hemolytic plaque-forming cells from human peripheral blood mononuclear cells (1981) (41)
Infectious complications and immunodeficiency in patients with human T‐cell lymphotropic virus I‐associated adult T‐cell leukemia/lymphoma (1995) (40)
Impaired in vitro lymphocyte transformation in patients with ataxia-telangiectasis. (1966) (40)
Adult T cell leukemia: a potential target for ricin A chain immunotoxins. (1985) (40)
Selective targeting of JAK/STAT signaling is potentiated by Bcl-xL blockade in IL-2-dependent adult T-cell leukemia (2015) (39)
Emerging Therapies: Spectrum of Applications of Monoclonal Antibody Therapy. (2000) (39)
Activation of leukemic pro-suppressor cells to become suppressor-effector cells. Influence of cooperating normal T cells. (1981) (39)
Albumin metabolism in patients with lymphoma. (1963) (39)
Immunodeficiency in the Wiskott-Aldrich syndrome. (1975) (39)
Vascular-Targeted Radioimmunotherapy with the Alpha-Particle Emitter 211At (2002) (39)
Participation of suppressor T cells in the immunosuppressive activity of a heteroantiserum to human Ia-like antigens (p23,30) (1980) (38)
Markedly additive antitumor activity with the combination of a selective survivin suppressant YM155 and alemtuzumab in adult T-cell leukemia. (2013) (38)
Molecular analysis of HTLV-I proviral integration and T cell receptor arrangement indicates that T cells in tropical spastic paraparesis are polyclonal. (1989) (38)
The anti-CD25 monoclonal antibody 7G7/B6, armed with the alpha-emitter 211At, provides effective radioimmunotherapy for a murine model of leukemia. (2006) (38)
Antibody-based therapy of leukaemia (2009) (38)
Suppressor T cells in the pathogenesis of hypogammaglobulinemia associated with a thymoma. (1975) (38)
A comparison of three radioimmunoassay techniques for the measurement of serum IgE. (1973) (37)
Preparation of 211At-labeled humanized anti-Tac using 211At produced in disposable internal and external bismuth targets. (1998) (37)
IL‐15‐dependent CD8+CD122+ T cells ameliorate experimental autoimmune encephalomyelitis by modulating IL‐17 production by CD4+ T cells (2014) (37)
Phase I trial of siplizumab in CD2-positive lymphoproliferative disease (2005) (37)
The role of alpha-fetoprotein and human chorionic gonadotropin in seminoma. (1978) (37)
Augmented efficacy of brentuximab vedotin combined with ruxolitinib and/or Navitoclax in a murine model of human Hodgkin’s lymphoma (2016) (36)
Lymphocyte-macrophage interaction in antigen induced in vitro lymphocyte transformation in patients with the Wiskott-Aldrich syndrome and other diseases with anergy. (1972) (36)
The role of the radioimmunoassay of serum alpha-fetoprotein and human chorionic gonadotropin in the intensive chemotherapy and surgery of metastatic testicular tumors. (1978) (35)
Early experience with anti-Tac in clinical renal transplantation. (1989) (35)
Effective treatment of a murine model of adult T-cell leukemia using 211At-7G7/B6 and its combination with unmodified anti-Tac (daclizumab) directed toward CD25. (2006) (35)
Plasma protein metabolism: regulation of synthesis, distribution and degradation. (1970) (35)
Development of an IL-15-autocrine CD8 T-cell leukemia in IL-15-transgenic mice requires the cis expression of IL-15Rα. (2011) (35)
Adult T-cell leukemia cells overexpress Wnt5a and promote osteoclast differentiation. (2013) (35)
Viral Activation of Interleukin-15 (IL-15): Characterization of a Virus-Inducible Element in the IL-15 Promoter Region (2000) (34)
Idiopathic edema. I. The occurrence of hypoalbuminemia and abnormal albumin metabolism in women with unexplained edema. (1972) (34)
The role of the kidney in the erythropoietic response to hypoxia in parabiotic rats. (1962) (34)
Combination therapy for adult T-cell leukemia-xenografted mice: flavopiridol and anti-CD25 monoclonal antibody. (2005) (34)
Normalization of antibody responsiveness in a patient with common variable hypogammaglobulinemia and HIV infection. (1987) (34)
IL-2Rα on One Cell Can Present IL-2 to IL-2Rβ/γc on Another Cell to Augment IL-2 Signaling (1998) (34)
Inhibition of human lymphocyte proliferation by the nonmitogenic lectin wheat germ agglutinin. (1980) (34)
Pretargeted α Emitting Radioimmunotherapy Using 213Bi 1,4,7,10-Tetraazacyclododecane-N,N′,N″,N‴-Tetraacetic Acid-Biotin (2004) (33)
Metabolic study of human IgE: evidence for an extravascular catabolic pathway. (1978) (33)
IL2-PE664Glu, a new chimeric protein cytotoxic to human-activated T lymphocytes. (1990) (33)
Erythrocytosis and hyperlipemia as manifestations of hepatic carcinoma. (1967) (33)
Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1 (2007) (33)
IL-2 and IL-15 blockade by BNZ-1, an inhibitor of selective γ-chain cytokines, decreases leukemic T-cell viability (2018) (32)
Cooperative interactions between the interleukin 2 receptor alpha and beta chains alter the interleukin 2-binding affinity of the receptor subunits. (1994) (32)
Preparation and in vivo evaluation of linkers for 211At labeling of humanized anti-Tac. (2001) (32)
A COMPARISON OF SOME PHYSICAL AND CHEMICAL PROPERTIES OF ERYTHROPOIESIS-STIMULATING FACTORS FROM DIFFERENT SOURCES. (1964) (32)
Homograft replacement of the mitral valve in young recipients: mid-term results. (2003) (32)
Some molecular characteristics of erythropoietin from different sources determined by inactivation ionizing radiation. (1963) (32)
Alpha-fetoprotein and human chorionic gonadotropin in the management of testicular tumors. (1977) (32)
The application of multicompartmental analysis to problems of clinical medicine. Combined clinical staff conference at the National Institutes of Health. (1968) (31)
Hypogammaglobulinemia associated with accelerated catabolism of IgG secondary to its inteaction with an IgG-reactive monoclonal IgM. (1971) (31)
Biologic properties of E myeloma proteins. (1971) (31)
Phase II Study of Alemtuzumab (CAMPATH-1) in Patients with HTLV-1–Associated Adult T-cell Leukemia/lymphoma (2016) (31)
Vaccination with Tumor Cells Expressing IL-15 and IL-15Rα Inhibit Murine Breast and Prostate Cancer (2014) (30)
Immunoglobulin A Production in Ataxia Telangiectasia (1965) (30)
Effective therapy for a murine model of human anaplastic large-cell lymphoma with the anti-CD30 monoclonal antibody, HeFi-1, does not require activating Fc receptors. (2006) (30)
Antileukemic effect of daclizumab in CD25 high-expressing leukemias and impact of tumor burden on antibody dosing. (2006) (30)
PROTEIN‐LOSING ENTEROPATHIES IN MALIGNANCY (1974) (30)
Activated clearance of a biotinylated macromolecular MRI contrast agent from the blood pool using an avidin chase. (2003) (30)
The role of cell-surface receptors in the transport and catabolism of immunoglobulins. (1972) (29)
THE METABOLISM OF ERYTHROPOIETIN IN PATIENTS WITH ANEMIA DUE TO DEFICIENT ERYTHROPOIESIS. (1964) (29)
Malignant germ cell tumors of the ovary and testis. An immunohistologic study of 69 cases. (1979) (29)
Targeting the interleukin-15 system in rheumatoid arthritis. (2005) (29)
Resolution of longstanding protein-losing enteropathy in a patient with intestinal lymphangiectasia after treatment for malignant lymphoma (1981) (29)
PROTEIN-LOSING ENTEROPATHY SECONDARY TO CONSTRICTIVE PERICARDITIS IN CHILDHOOD. (1964) (29)
Albumin metabolism in patients with Whipple's disease. (1966) (29)
Selective killing of human T-lymphotropic virus-I infected leukemic T-cells by monoclonal anti-interleukin 2 receptor antibody-ricin A chain conjugates: potentiation by ammonium chloride and monensin. (1986) (29)
Spontaneous Regression of a Monoclonal Proliferation of Large Granular Lymphocytes Associated With Reversal of Anemia and Neutropenia (1986) (29)
Successful treatment with acyclovir of an immunodeficient patient infected simultaneously with multiple herpesviruses. (1981) (29)
The value of serial measurement of both human chorionic gonadotropin and alpha-fetoprotein for monitoring germinal cell tumors. (2002) (28)
Human B lymphocytes express the p75 component of the interleukin 2 receptor. (1990) (28)
Mutation of epigenetic regulators TET2 and MLL3 in patients with HTLV-I-induced acute adult T-cell leukemia (2016) (28)
Micro-MRI methods to detect renal cysts in mice. (2004) (28)
T-cell receptors for cytokines: targets for immunotherapy of leukemia/lymphoma. (2000) (28)
Isospora belli enteric infection in patients with human T-cell leukemia virus type I-associated adult T-cell leukemia. (1988) (27)
Development of a highly efficacious vaccinia-based dual vaccine against smallpox and anthrax, two important bioterror entities (2010) (27)
Augmented efficacy with the combination of blockade of the NOTCH-1 pathway, Bortezomib and Romidepsin in a murine MT-1 adult T cell leukemia model (2014) (26)
Trans-endocytosis of intact IL-15Rα–IL-15 complex from presenting cells into NK cells favors signaling for proliferation (2019) (26)
Neoplasms of immunoregulatory cells. (1979) (26)
Protein-losing enteropathy and kinetic studies of plasma protein metabolism. (1972) (26)
Immunochemical determination of human chorionic gonadotropin and alpha-fetoprotein in sera and tumors of patients with testicular cancer. (1978) (25)
IFN Regulatory Factor 4 Participates in the Human T Cell Lymphotropic Virus Type I-Mediated Activation of the IL-15 Receptor α Promoter1 (2002) (25)
Lymphokine receptors: a target for immunotherapy of lymphomas. (1994) (25)
Gastrointestinal protein loss demonstrated by Cr-51-labelled albumin. (1961) (25)
Tumor-associated antigen levels (carcinoembryonic antigen, human chorionic gonadotropin, and alpha-fetoprotein) antedating the diagnosis of cancer in the Framingham study. (1977) (25)
Effect of temperature on erythropoiesis and red cell survival in the frog. (1962) (24)
IL-15 Serves as a Costimulator in Determining the Activity of Autoreactive CD8 T Cells in an Experimental Mouse Model of Graft-versus-Host-Like Disease1 (2008) (24)
Interleukin-2 receptor-directed therapies for cutaneous lymphomas. (2003) (24)
Model of Adult T-Cell Leukemia by a Mechanism other than Blockade of IL-2/IL-2R � Interaction (2013) (24)
Suppression of human T and B lymphocyte activation by Agaricus bisporus lectin. I. Suggestive evidence for a surface "suppressor" receptor in human lymphocytes. (1981) (24)
T-cell receptor gene rearrangement in T-cell large granular leukocyte leukemia: preferential V alpha but diverse J alpha usage in one of five patients. (1994) (24)
IL-21-driven neoplasms in SJL mice mimic some key features of human angioimmunoblastic T-cell lymphoma. (2015) (24)
Mik-beta 1(Fv)-PE40, a recombinant immunotoxin cytotoxic toward cells bearing the beta-chain of the IL-2 receptor. (1992) (24)
Carcinoembryonic antigen and alpha-fetoprotein in the diagnosis of gastric and colonic cancer: a comparative clinical evaluation. (1974) (23)
Clonality and lymphoproliferative lesions. (1986) (23)
IL-2R alpha on one cell can present IL-2 to IL-2R beta/gamma(c) on another cell to augment IL-2 signaling. (1998) (23)
Prophylactic use of monoclonal anti-IL-2 receptor antibody in cadaveric renal transplantation. (1989) (23)
A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation. (1991) (23)
IL-2-PE40 prevents the development of tumors in mice injected with IL-2 receptor expressing EL4 transfectant tumor cells. (1990) (22)
Human gamma-chain genes are rearranged in leukaemic T cells and map to the short arm of chromosome 7. (1985) (22)
Serum alpha-fetoprotein in patients with massive hepatic necrosis. (1977) (22)
Activators of protein kinase C and 5‐azacytidine induce IL‐2 receptor expression on human T lymphocytes (1985) (22)
How does interleukin 15 contribute to the pathogenesis of HTLV type 1-associated myelopathy/tropical spastic paraparesis? (2000) (22)
Identification of a γc Receptor Antagonist that Prevents Reprogramming of Human Tissue-resident Cytotoxic T Cells by IL15 and IL21. (2020) (22)
Protection by universal influenza vaccine is mediated by memory CD4 T cells. (2018) (22)
The Effect of Splenectomy on Erythropoiesis in the Dog (1960) (22)
Plasmid-encoded interleukin-15 receptor alpha enhances specific immune responses induced by a DNA vaccine in vivo. (2009) (22)
A multi-valent vaccinia virus-based tuberculosis vaccine molecularly adjuvanted with interleukin-15 induces robust immune responses in mice. (2009) (21)
Production of human suppressor T cell hybridomas. (1982) (21)
Characterization of a soluble suppressor of human B cell immunoglobulin biosynthesis produced by a continuous human suppressor T cell line (1981) (21)
Intestinal lymphangiectasia: a protein-losing enteropathy with hypogammaglobulinemia, lymphocytopenia and impaired homograft rejection (1968) (21)
Smallpox vaccine with integrated IL-15 demonstrates enhanced in vivo viral clearance in immunodeficient mice and confers long term protection against a lethal monkeypox challenge in cynomolgus monkeys (2010) (21)
Current concepts in immunoregulatory T-cell neoplasms. (1979) (21)
Immunologic deficiency diseases. (1971) (21)
IL-15 Expands Unconventional CD8ααNK1.1+ T Cells but Not Vα14Jα18+ NKT Cells1 (2008) (21)
JAK/STAT pathway directed therapy of T-cell leukemia/lymphoma: Inspired by functional and structural genomics (2017) (21)
Lymphocytosis of large granular lymphocytes. (1986) (20)
Paracrine and Transpresentation Functions of IL-15 Are Mediated by Diverse Splice Versions of IL-15Rα in Human Monocytes and Dendritic Cells* (2012) (20)
Variable amplification of immunoglobulin lambda light-chain genes in human populations. (1983) (20)
Deletion of the p16INK4A gene in ex vivo acute adult T cell lymphoma/leukemia cells and methylation of the p16INK4A promoter in HTLV type I-infected T cell lines. (2000) (20)
Receptor-Directed Therapy of T-Cell Leukemias and Lymphomas (2008) (20)
Sensitivity of hypothalamic paraventricular nucleus to C- and N-terminal angiotensin fragments: vasopressin release and drinking. (1998) (19)
Effect of thyroid administration on erythropoiesis in the dog. (1962) (19)
Short-course IL-15 given as a continuous infusion led to a massive expansion of effective NK cells: implications for combination therapy with antitumor antibodies (2021) (19)
Inducible knockout of the interleukin-2 receptor alpha chain: expression of the high-affinity IL-2 receptor is not required for the in vitro growth of HTLV-I-transformed cell lines. (1997) (19)
Stimulation of immunoglobulin biosynthesis in human B cells by wheat germ agglutinin. I. Evidence that WGA can produce both a positive and negative signal for activation of human lymphocytes. (1981) (19)
Mycophenolate Mofetil in Epidermolysis bullosa acquisita (2003) (19)
Cryofibrinogenemia, multiple dysproteinemias, and hypervolemia in a patient with a primary hepatoma. (1966) (18)
The promiscuous IL-2/IL-15 receptor: a target for immunotherapy of HTLV-I-associated disorders. (1996) (18)
Erythropoietin Assays Using Iron59 Incorporation into Blood and Spleen of the Polycythemic Mouse (1962) (18)
Protein‐Losing Enteropathy and Malabsorption in Regional Enteritis: Cure by Limited Ileal Resection (1973) (18)
OLIGOMERIZATION OF IL-2Rα (2002) (18)
Differential effects of IL-2 and IL-15 on expression of IL-2 receptor alpha. (2001) (18)
Preparation and in vivo evaluation of novel linkers for 211At labeling of proteins. (2004) (18)
Lymphocyte ecto-5'-nucleotidase activity as a marker of B-cell maturation. (1979) (18)
Differential contribution of angiotensinergic and cholinergic receptors in the hypothalamic paraventricular nucleus to osmotically induced AVP release. (1998) (18)
Clinical manufacturing of recombinant human interleukin 15. I. Production cell line development and protein expression in E. coli with stop codon optimization (2012) (18)
Metabolism of Immunoglobulins (Part 3 of 3) (1969) (18)
ABCs of Radioisotopes Used for Radioimmunotherapy: α- and β-Emitters (2003) (18)
Use of an antibody against the soluble interleukin 2 receptor alpha subunit can modulate the stability and biodistribution of interleukin-2. (1999) (17)
Factors stimulating erythropoiesis in frogs. (1963) (17)
Distribution of human leukocyte antigens in a population of black patients with human T-cell lymphotrophic virus type I-associated adult T-cell leukemia/lymphoma. (1996) (17)
Radiographic manifestations of primary acquired hypogammaglobulinemia. (1973) (17)
Spontaneous regression of a monoclonal proliferation of large granular lymphocytes associated with reversal of anemia and neutropenia. (1986) (17)
Use of yttrium-90-labeled anti-Tac antibody in primate xenograft transplantation. (1990) (17)
Improved renal clearance and tumor targeting of 99mTc-labeled anti-Tac monoclonal antibody Fab by chemical modifications. (2002) (17)
CLINICAL USE OF A.F.P. AND H.C.G. IN TESTICULAR TUMOURS OF GERM-CELL ORIGIN (1978) (17)
Immunological aspects of purine metabolism. (1977) (16)
Effect of Temperature on Red Cell Survival in the Alligator (1962) (16)
A20 and RBX1 Regulate Brentuximab Vedotin Sensitivity in Hodgkin Lymphoma Models (2020) (16)
Anti-IL-2 receptor monoclonal antibody (anti-Tac) treatment of T-cell lymphoma. (1994) (16)
The interleukin-2 receptor on malignant cells: a target for diagnosis and therapy. (1986) (16)
Systemic radioimmunotherapy using a monoclonal antibody, anti-Tac directed toward the alpha subunit of the IL-2 receptor armed with the alpha-emitting radionuclides (212)Bi or (211)At. (2004) (16)
Dendritic cell-derived interleukin-15 is crucial for therapeutic cancer vaccine potency (2014) (16)
Differential IL-2 receptor expression in renal allograft recipients treated with an anti-IL-2-receptor antibody. (1989) (16)
Effect of Anti-CD 25 Antibody Daclizumab in the Inhibition of Inflammation and Stabilization of Disease Progression in Multiple Sclerosis (2009) (16)
Synthesis and biodistribution study of a new 211At-calix[4]arene complex (2000) (16)
Leukemia of non-T lineage natural killer cells. (1988) (15)
Selective elimination in vitro of alloresponsive T cells to human transplantation antigens by toxin or radionuclide conjugated anti-IL-2 receptor (Tac) monoclonal antibody. (1990) (15)
Interleukin-2 receptors: biology and therapeutic potentials. (1987) (15)
Demonstration of delta rec-pseudo J alpha rearrangement with deletion of the delta locus in a human stem-cell leukemia (1989) (15)
Colorectal carcinoma rearranges cell surface protein topology and density in CD4+ T cells. (2007) (15)
Erratum: Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon β (Proceedings of the National Academy of Sciences of the United States of America (June 8, 2004) 101:23 (8705-8708)) (2004) (15)
Recombinant Human IL-15 Promotes in Vivo Expansion of Adoptively Transferred NK Cells in a First-in-Human Phase I Dose Escalation Study in Patients with AML (2012) (14)
Metabolic studies of a heavy chain disease protein. (1969) (14)
Favorable effects of glycolate conjugation on the biodistribution of humanized antiTac Fab fragment. (1999) (14)
CONSTRICTIVE PERICARDITIS AND PROTEIN LOSING ENTEROPATHY (1975) (14)
Quantitative measurement of erythropoiesis in the dog. (1960) (14)
Simultaneous radioimmunoassay for carcinoembryonic antigen (CEA) and alpha-fetoprotein (alphaFP) in neoplasms of the gastro-intestinal tract. (1974) (14)
Kaposi's sarcoma in human T-cell leukemia virus type I-associated adult T-cell leukemia. (1990) (14)
Metabolism of infused serum albumin in the hypoproteinemia of gastro-intestinal protein loss and in analbuminemia. (1961) (14)
Modifications in synthesis strategy improve the yield and efficacy of geldanamycin-herceptin immunoconjugates. (2002) (14)
Radiation therapy for the management of patients with HTLV-1-associated adult T-cell leukemia/lymphoma. (2012) (13)
MHC I Expression Regulates Co-clustering and Mobility of Interleukin-2 and -15 Receptors in T Cells. (2016) (13)
Detection of receptor trimers on the cell surface by flow cytometric fluorescence energy homotransfer measurements. (2005) (13)
IL-15 expands unconventional CD8alphaalphaNK1.1+ T cells but not Valpha14Jalpha18+ NKT cells. (2008) (13)
The role of the multichain IL-2 receptor complex in the control of normal and malignant T-cell proliferation. (1987) (13)
Cardiac involvement with human T-cell lymphotrophic virus type-1-associated adult T-cell leukemia/lymphoma: The NIH experience (2008) (13)
Interleukin 15 Pharmacokinetics and Consumption by a Dynamic Cytokine Sink (2020) (13)
Combination of 9-aminoacridine with Campath-1H provides effective therapy for a murine model of adult T-cell leukemia (2014) (13)
IL-2 receptors preassemble and signal in the ER/Golgi causing resistance to antiproliferative anti–IL-2Rα therapies (2019) (13)
Preparation and in vivo evaluation of a novel stabilized linker for 211At labeling of protein. (2006) (13)
The meandering 45-year odyssey of a clinical immunologist. (2003) (13)
Bismuth-212-labeled anti-Tac monoclonal antibody : a-Particle-emitting radionuclides as modalities for radioimmunotherapy ( interleukin 2 receptors / adult T-cell leukemia / diethylenetriaminepentaacetic acid (13)
The multichain interleukin 2 receptor. A target for immunotherapy in lymphoma, autoimmune disorders, and organ allografts [clinical reference]. (1990) (13)
Distinct spatial relationship of the interleukin-9 receptor with interleukin-2 receptor and major histocompatibility complex glycoproteins in human T lymphoma cells. (2014) (13)
Synthesis and evaluation of antiproliferative activity of a geldanamycin-Herceptin immunoconjugate. (2000) (13)
The IL-2/IL-2 receptor system: a target for rational immune intervention. (1993) (12)
Characteristics of Multiple Myeloma as an Immunodeficiency Disease (1980) (12)
Large granular lymphocyte proliferation: an analysis of T-cell receptor gene arrangement and expression and the effect of in vitro culture with inducing agents (1988) (12)
PROLONGATION OF GRAFT SURVIVAL IN PRIMATE ALLOGRAFT TRANSPLANTATION BY YTTRIUM‐90-LABELED ANTI‐TAC IN CONJUNCTION WITH GRANULOCYTE COLONY‐STIMULATING FACTOR (1992) (12)
Gain-of-function CCR 4 mutations in adult T cell leukemia / lymphoma (2014) (12)
The Interleukin‐2 Receptor: A Target for Immunotherapy (1993) (12)
Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors (2021) (11)
Immunometabolism at the Nexus of Cancer Therapeutic Efficacy and Resistance (2021) (11)
NF-κB–induced R-loop accumulation and DNA damage select for nucleotide excision repair deficiencies in adult T cell leukemia (2021) (11)
Identification of a novel receptor/signal transduction pathway for IL‐15/T in mast cells. (1996) (11)
Phase II trial of daclizumab in human T-cell lymphotropic virus type-1 (HTLV-1)-associated adult T-cell leukemia/lymphoma (ATL). (2010) (11)
Alternative and canonical NF-kB pathways DNA-binding hierarchies networks define Hodgkin lymphoma and Non-Hodgkin diffuse large B Cell lymphoma respectively (2019) (11)
The interaction of interleukin 2 with its receptor in the generation of suppressor T cells in antigen-specific and antigen-nonspecific systems in vitro. (1989) (10)
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one (2016) (10)
Loss of Cytotoxicity and Gain of Cytokine Production in Murine Tumor-Activated NK Cells (2014) (10)
Neoplasms of immunoregulatory T cells in clinical investigation. (1980) (10)
Essential role of the linear ubiquitin chain assembly complex and TAK1 kinase in A20 mutant Hodgkin lymphoma (2020) (10)
Sustained suppression of SHIV89.6P replication in macaques by vaccine-induced CD8+ memory T cells (2008) (10)
Comparison of anti-Tac and anti-transferrin receptor-conjugated liposomes for specific drug delivery to adult T-cell leukemia (1989) (10)
The multichain interleukin-2 receptor: a target for immunotherapy of patients receiving allografts. (1989) (10)
Synthesis of plasma proteins by hepatectomized dogs. (1966) (10)
Results From a First‐in‐Human Study of BNZ‐1, a Selective Multicytokine Inhibitor Targeting Members of the Common Gamma (γc) Family of Cytokines (2020) (10)
Immunoregulatory functions of cultured human T lymphocytes. (1980) (9)
Improved biodistribution of 125I-labeled anti-Tac disulfide-stabilized Fv fragment by blocking its binding to the alpha subunit of the interleukin 2 receptor in the circulation with preinjected humanized anti-Tac IgG. (1997) (9)
FURTHER CHARACTERIZATION OF NEOPLASTIC HELPER T CELLS FROM PATIENTS WITH THE SÉZARY SYNDROME (1977) (9)
EBV-Related Lymphoproliferative Disease Complicating Therapy with Siplizumab, a Novel Anti-CD2 Mediated T- and NK-Cell Depleting Agent, in Patients with T-Cell Malignancies. (2007) (9)
The multichain interleukin-2 receptor: from the gene to the bedside. (1986) (9)
Differential specificity of lymphocytotoxins from patients with systemic lupus erythematosus and inflammatory bowel disease. (1976) (9)
Evaluation of human chorionic gonadotropin and alpha fetoprotein in benign and malignant testicular disorders. (1978) (9)
Blockade of IL-15 Utilizing Bnz-1, a Selective γ-Chain Inhibiting Peptide, Is Safe and Has Clinical Activity in Patients with T-Cell Large Granular Lymphocytic Leukemia (T-LGLL): Results of a Phase I/II Multi-Center Clinical Trial (2019) (9)
Janus Kinase Inhibitor Tofacitinib Shows Potent Efficacy in a Mouse Model of Autoimmune Lymphoproliferative Syndrome (ALPS) (2015) (9)
A Monoclonal Antibody to the Human Receptor for T Cell Growth Factor (1984) (9)
The role of the kidney in the metabolism of serum proteins. (1972) (8)
A pre-translational defect in a case of human mu heavy chain disease. (1986) (8)
Immunoglobulin genes: Rearrangement and translocation in human lymphoid malignancy (2004) (8)
Yttrium-90 Radiolabeled Humanized Monoclonal Antibody to CD25 in Refractory and Relapsed Hodgkin’s Lymphoma (2008) (8)
Interleukin-2 receptor expression in retrovirus associated adult T-cell leukemia. (1984) (8)
Fetal Hemoglobin and α-Fetoprotein in Various Malignancies (1977) (8)
Protective-antigen (PA) based anthrax vaccines confer protection against inhalation anthrax by precluding the establishment of a systemic infection (2013) (8)
KINETIC STUDIES OF IMMUNOGLOBULIN METABOLISM IN IMMUNOLOGIC DEFICIENCY (1969) (8)
Interleukin-15 Constrains Mucosal T Helper 17 Cell Generation: Influence of Mononuclear Phagocytes (2015) (8)
Improving Sun Protection Behaviour in Children: Study Design and Baseline Results of a Randomized Trial in Italian Elementary Schools (2003) (8)
Lymphatic drainage imaging of the breast cancer in mice using the micro-magnetic resonance mammo-lymphangiography using a nano-size contrast agent (2004) (8)
Receptor β IL-2 / 15 R Monoclonal Antibody Directed to the Paraparesis : Implications for Therapy with a I-Associated Myelopathy / Tropical Spastic Human T Lymphotropic Virus Type Involvement of IL-15 in the Pathogenesis of (1999) (8)
Comparison of anti-Tac and anti-transferrin receptor-conjugated liposomes for specific drug delivery to adult T-cell leukemia. (1989) (7)
T-lymphocyte interleukin 2-dependent tyrosine protein kinase signal transduction involves the activation of p 561 ck ( interleukin 2 receptor / tyrosine phosphorylation ) (7)
Lymphokine receptor-directed therapy: a model for immune intervention in leukemia, autoimmunity, and immunodeficiency. (1991) (7)
ABCs of radioisotopes used for radioimmunotherapy: alpha- and beta-emitters. (2003) (7)
A novel model of alternative NF-κB pathway activation in anaplastic large cell lymphoma (2020) (7)
Anti-HER2 radioimmunotherapy. (2000) (7)
Immunodeficiency: immunoregulation and immunogenetics. (1986) (7)
The value of serial measurement of both human chorionic gonadotropin and alpha‐fetoprotein for monitoring germinal cell tumors (1976) (7)
Isolation of human alpha-fetoprotein in two fractionation steps and demonstration of homogeneity. (1979) (7)
An attempt to produce hypersplenism in the dog, using methylcellulose. (1961) (7)
Membrane Potential Distinctly Modulates Mobility and Signaling of IL-2 and IL-15 Receptors in T Cells. (2018) (7)
Mechanisms of Lymphocyte Activation and Immune Regulation IV (1992) (7)
Human T-cell lymphotropic virus type I-associated adult T-cell leukemia. The Joseph Goldberger Clinical Investigator Lecture. (1995) (7)
The interleukin-2 receptor on normal and malignant lymphocytes. (1987) (7)
Clinical trial of a humanized anti‐IL‐2/IL‐15 receptor β chain in HAM/TSP (2019) (7)
correction: Requirement for IRF-1 in the microenvironment supporting development of natural killer cells (1998) (7)
Blockade of the interleukin-2 receptor by anti-Tac antibody inhibits the generation of antigen-nonspecific suppressor T cells in vitro. (1988) (7)
Immunoglobulin metabolism in disease. (1975) (7)
Resolution of longstanding protein-losing enteropathy in a patient with intestinal lymphangiectasia after treatment for malignant lymphoma. (1981) (6)
Phase I/II study of Yttrium-90 labeled humanized anti-Tac (HAT) monoclonal antibody and calcium DTPA in CD25-expressing malignancies (2006) (6)
Detection of channel proximity by nanoparticle-assisted delaying of toxin binding; a combined patch-clamp and flow cytometric energy transfer study (2005) (6)
A very long-acting IL-15: implications for the immunotherapy of cancer (2022) (6)
Large granular lymphocyte proliferation: an analysis of T-cell receptor gene arrangement and expression and the effect of in vitro culture with inducing agents. (1988) (6)
Prospective evaluation of some candidate tumor markers in the diagnosis of pancreatic cancer (1980) (6)
Therapie der lymphomatoiden Papulose mit Bade-PUVA-(Balneo-)Photochemotherapie (2000) (6)
Regression of Adult T-Cell Leukemia with Anti-CD25 Recombinant Immunotoxin LMB-2 Preceded by Chemotherapy (2011) (6)
Phase 1/2 study of alemtuzumab with dose-adjusted EPOCH in untreated aggressive T and NK cell lymphomas (2019) (6)
Methods for the study of the metabolism of immunoglobulins. (1985) (6)
Purification and Physical Characterization of Human Alpha‐fetoprotein from Cord Blood and from Ascites Fluid of Individuals with Hepatocellular Carcinoma (1978) (5)
Human T cell lymphotropic virus type I Tax protein trans-activates interleukin 15 gene transcription through an NFk B site (1998) (5)
A monoclonal antibody, anti-Tac, blocks the action and membrane binding of human interleukin-2 (IL-2) (1982) (5)
Human T Cell Lymphotropic Virus Type I Tax Activates IL-15Ra Gene Expression Through an NF- kB Site (2001) (5)
Malabsorption and protein-losing enteropathy in a child with X-linked agammaglobulinemia. (1975) (5)
Multiple sclerosis, retroviruses, and PCR. The HTLV-MS Working Group. (1991) (5)
Augmented interleukin ( IL )-15 R α expression by CD 40 activation is critical in synergistic CD 8 T-cell mediated antitumor activity of anti-CD 40 antibody with IL-15 in TRAMP-C 2 tumors in mice (2013) (5)
1992 Stohlman Memorial Lecture: targeting the IL-2 receptor. (1993) (5)
The immunological deficiency state in ataxia-telangiectasia. (1971) (5)
A New Domain in the Toll/IL-1R Domain-Containing Adaptor Inducing Interferon-ß Factor Protein Amino Terminus Is Important for Tumor Necrosis Factor-a Receptor-Associated Factor 3 Association, Protein Stabilization and Interferon Signaling (2014) (5)
Germinal epimutation of Fragile Histidine Triad (FHIT) gene is associated with progression to acute and chronic adult T-cell leukemia diseases (2021) (5)
Preclinical evaluation of an anti-CD25 monoclonal antibody, 7G7/B6, armed with the beta-emitter, yttrium-90, as a radioimmunotherapeutic agent for treating lymphoma. (2009) (5)
The relationship of IgA and IgE deficiency. (1975) (5)
90Y-Daclizumab (Anti-CD25), High-Dose Carmustine, Etoposide, Cytarabine, and Melphalan Chemotherapy and Autologous Hematopoietic Stem Cell Transplant Yielded Sustained Complete Remissions in 4 Patients with Recurrent Hodgkin's Lymphoma. (2020) (5)
Prolongation of primate renal allografts with anti-Tac monoclonal antibody. (1988) (5)
Minimum degree of overlap between IL‐9R and IL‐2R on human T lymphoma cells: A quantitative CLSM and FRET analysis (2018) (5)
The 1977 Bela Schick Memorial Lecture: disorders of suppressor cells in the pathogenesis of immunodeficiency, autoimmune and allergic diseases: human disease associated with disorders of an immunological breaking system. (1977) (5)
Interleukin-2 receptors on activated malignant and normal B-cells. (1984) (5)
Phase I dose escalation study of the anti-CD2 monoclonal antibody, siplizumab, with DA-EPOCH-R in aggressive peripheral T-cell lymphomas (2018) (5)
Characterization of a soluble suppressor of human B cell function produced by a continuous human suppressor T cell line. II. Evidence for suppression through a direct action of CTC-SISS-B on human B cells. (1982) (5)
lymphohematopoietic cells CD7+, CD4-, CD8- acute leukemia: a syndrome of malignant pluripotent (2011) (4)
NK cells prevent T cell lymphoma development in T cell receptor-transgenic mice. (2020) (4)
IL-2 receptors in adult T-cell leukemia: a target for immunotherapy. (1987) (4)
Radiolabeled CHXB-2E4 is stable in vivo and is a suitable immunoconjugate for testing α-particle-emitting bismuth radionuclides in interleukin-2 receptor targeted immunotherapy (1994) (4)
Loss of suppressor t cells in adult nzb/w mice. Abstr. (1976) (4)
Advances in diagnosis of hematologic malignancies. (1986) (4)
GVL for ATL? (2013) (4)
Allergic gastroenteropathy. (1968) (4)
Genome-wide CRISPR screen identifies CDK6 as a therapeutic target in Adult T-cell leukemia/lymphoma. (2021) (4)
Genetic Rearrangements of Human Immunoglobulin Genes (1984) (4)
Catabolism of Immunoglobulins (1971) (4)
A novel means of favorably tipping the balance between cytopathic and regulatory T cells. (2003) (4)
Regulation of the humoral immune response: from immunoglobulin genes to regulatory T cell networks. (1983) (4)
Neurological Consequences of Cytokine Release Syndrome Following Subcutaneous Recombinant IL-15 and Haploidentical Donor Natural Killer Cell Therapy for Advanced Acute Myeloid Leukemia (2017) (4)
A Phase I Study of Intravenous NCI IL-15 to Enhance Adoptively Transferred NK Cells Uncovers Defects in CD16 Triggered IFNγ Production and Competition Between Donor NK and Recipient T Cells (2015) (4)
Constrictive pericarditis and protein losing enteropathy. An imitator of intestinal lymphangiectasis. (1975) (4)
Tofacitinib, a Janus Kinase Inhibitor Demonstrates Efficacy in an IL-15 Transgenic Mouse Model that Recapitulates Pathologic Manifestations of Celiac Disease (2012) (4)
The interleukin-2 receptor: a target for immunotherapy. (1992) (3)
Enhanced efficacy of JAK1 inhibitor with mTORC1/C2 targeting in smoldering/chronic adult T cell leukemia (2020) (3)
Abstract 1332: Interleukin-15 enhances rituximab-dependent cytotoxicity ex vivo and in vivo against a mouse lymphoma expressing human CD20 (2015) (3)
DYSFUNCTION OF SUPPRESSOR MECHANISMS ASSOCIATED WITH IMMUNODEFICIENCY AND AUTOIMMUNITY (1977) (3)
A gain-of-function CCR4 mutations in adult T-cell leukemia/lymphoma (ATL) enhance the chemotactic abilities and P13K/AKT activation (2015) (3)
Evidence for Distinct IL‐2 Receptors in Induction versus Maintenance of LAK Function (1988) (3)
Cellular Localization of AFP and HCG in Germ Cell Tumors of the Testis and Ovary (1978) (3)
alpha-Fetoprotein values in monkey (Macaca mulatta) pregnancy. (1977) (3)
Fetal hemoglobin and alpha-fetoprotein in various malignancies. (1977) (3)
Role of Recipient CD8+ T Cell Exhaustion in the Rejection of Adoptively Transferred Haploidentical NK Cells (2016) (3)
Analysis of Human Natural Killer Cell Metabolism. (2020) (3)
the Life and Death of Normal and Neoplastic Lymphocytes: Implications for Cancer Therapy (2015) (3)
Protein-losing gastroenteropathy. (1964) (3)
Genome-wide CRISPR screens identify CD48 defining susceptibility to NK cytotoxicity in peripheral T-cell lymphomas (2022) (3)
Abstract CT082: Phase (Ph) I/Ib study of NIZ985 with and without spartalizumab (PDR001) in patients (pts) with metastatic/unresectable solid tumors (2019) (3)
Transmembrane Signals Mediated by IL-2 and IL-15 Control the Life and Death of Lymphocytes (2005) (3)
Human B-cell precursor leukemias. (1984) (3)
Loss of suppressor T cells in the pathogenesis of the autoimmunity of NZB/W mice. (1978) (3)
The Metabolism of IgE (1976) (3)
Construction of human suppressor T cell hybridomas. (1983) (3)
Isolation and expression of complementary DNAs encoding the human interleukin 2 receptor. (1985) (3)
Engagement of lymphoma T cell receptors causes accelerated growth and the secretion of an NK cell-inhibitory factor (2020) (3)
Co-expression of Interleukin-15 Enhances the Protective Immune Responses Induced by Immunization with a Murine Malaria MVA-Based Vaccine Encoding the Circumsporozoite Protein (2015) (3)
Developmental hierarchy ofimmunoglobulin generearrangements inhumanleukemic pre-B-cells (1981) (2)
18 Induction of the IL-9 Gene by HTLV-I Tax Stimulates the Spontaneous Proliferation of Primary ATL Cells by a Paracrine Mechanism (2007) (2)
1988 Presidential address of the Clinical Immunology Society: clinical immunology is everywhere and nowhere--strength or weakness? (1989) (2)
In vivo anti-interleukin-2 receptor (anti-Tac) therapy is immunosuppressive, but not tolerogenic. (1989) (2)
Abnormalities of immunoregulatory cells in immunodeficiency disease and cancer. (1981) (2)
In vitro interaction with antigen suppresses the differentiation of chronic lymphocytic leukemia cells secreting monoclonal anti-sheep red blood cell antibody. (1983) (2)
Alemtuzumab (Campath 1-H) in Patients with HTLV-1 Associated Adult T-Cell Leukemia/Lymphoma. (2008) (2)
Primary amyloidosis. (1968) (2)
Bench-to-bedside translation of interleukin-15 for immunotherapy: principles and challenges (2020) (2)
Clinical trial of a humanized monoclonal anti-IL15Rβ (CD122), in HTLV-1 associated myelopathy/ tropical spastic paraparesis (HAM/TSP) (2014) (2)
18 – ABNORMALITIES OF IMMUNOGLOBULIN METABOLISM (1970) (2)
Anti-TAC MOAB prolongs renal allografts in cynomolgus monkeys. (1989) (2)
The arrangement of immunoglobulin, T cell antigen receptor, and interleukin 2 receptor genes in human lymphoid neoplasms. (1986) (2)
CITN11-02 interim trial results: subcutaneous administration of recombinant human IL-15 (rhIL-15) is associated with expansion of peripheral blood CD56+ NK cells and CD8+ T cells (2015) (2)
IL-2 receptor expression in the haematologic malignancies: a target for immunotherapy. (1989) (2)
IL-15 Trans-Presentation Is an Autonomous, Antigen-Independent Process (2021) (2)
Phase I study of recombinant interleukin-15 in combination with checkpoint inhibitors nivolumab and ipilimumab in subjects with refractory cancers. (2018) (2)
Yttrium-90 Radiolabeled Daclizumab, An Anti-CD25 Monoclonal Antibody, Provides Effective Therapy for Refractory and Relapsed Hodgkin's Lymphoma, (2011) (2)
Lymphokine receptor-directed therapy: A model of immune intervention (1990) (2)
Results of the second international study on the W.H.O. alpha-foetoprotein standard. (1978) (2)
Oligomerization of IL-2Ralpha. (2002) (2)
Disorders of Suppressor T Cells in Immunodeficiency and Malignancy (1980) (2)
The multisubunit interleukin-2 receptor: a target for immunotherapy (1991) (2)
CHAPTER 5 – T-T INTERACTIONS IN THE GENERATION OF HUMAN SUPPRESSOR EFFECTOR CELLS IN VITRO (1979) (2)
The metabolism of tumour related proteins (1976) (2)
A phase II study of the efficacy and toxicity of alemtuzumab for the therapy of human T cell lymphotrophic virus-1 (HTLV-1)-associated adult T-cell leukemia/lymphoma (ATL). (2006) (2)
EGR1 Addiction in Diffuse Large B-cell Lymphoma (2021) (2)
Interleukin-15 augments NK cell–mediated ADCC of alemtuzumab in patients with CD52+ T-cell malignancies (2022) (2)
The mechanism of intestinal uptake and transcellular transport of IgG in the neonatal rat. (1972) (2)
Methods to avoid adverse effect of circulating antigen on biodistribution of 125I-labeled antiTac dsFv: preinjection of intact antibody versus clearance of antigen with adivin-biotin system. (1999) (2)
Selective Dependence of H2-M3–Restricted CD8 Responses on IL-15 (2012) (2)
Sheep lung as xenograft oxygenator of human blood: An ex vivo study (1995) (2)
CITN11-02 interim trial results: subcutaneous administration of recombinant human IL-15 (rhil-15) is associated with robust expansion of peripheral blood CD56+ NK cells (2014) (2)
Phase 1 Study of Subcutaneous Recombinant Human (rh) Interleukin-15 and Intravenous Alemtuzumab in Patients with Rrelapsed/Refractory T-Cell Lymphoma (2020) (2)
Metabolism of Immunoglobulins (Part 1 of 3) (1969) (2)
Effective Cytotoxicity of Dendritic Cells against Established T Cell Lymphomas in Mice (2021) (2)
Janus Kinase Inhibitor Tofacitinib Shows Potent Efficacy in a Mouse Model of Autoimmune Lymphoproliferative Syndrome (ALPS) (2015) (2)
Interleukin-15 Signaling Augments Dendritic Cell Vaccination against HER2/Neu by Inducing Her2/Neu Antibodies (2010) (2)
Strategies for the treatment of intraocular inflammatory disease. (1998) (2)
Combination of 9-aminoacridine with Campath-1H provides effective therapy for a murine model of adult T-cell leukemia (2014) (1)
Essential Clinical Immunology: Immune Regulation (2009) (1)
The regulation of the human humoral immune response and functional assays for its assessment. (1983) (1)
Co-expression of IL-15 and IL-15R{alpha} on pancreatic {beta} islet cells induced insulin dependent diabetes mellitus in mice (2012) (1)
Regulation of synthesis of immunoglobulins (1976) (1)
IL-15 and anti-PD-1 augment the efficacy of agonistic intratumoral anti-CD40 in a mouse model with multiple TRAMP-C2 tumors. (2022) (1)
IL-2 Receptor-Directed Immunotherapy: A Model of Immune Intervention (1989) (1)
[Therapy of lymphomatoid papulosis with balneo-PUVA-photochemotherapy]]. (2000) (1)
In vitro and in vivo regulation of immunoglobulin synthesis (1984) (1)
Interleukhm-15/t utilizes a novel receptor/signal transduction pathway in mast cells (1996) (1)
429. Adenoviral-Mediated Interleukin-15 Receptor-α Gene Therapy of Murine Breast Cancer (2006) (1)
[Responders and nonresponders of ultraviolet A-1 therapy of acute exacerbated atopic eczema]. (1997) (1)
Radioimmunoassay of alpha fetoprotein in the diagnosis of malignancy. (1974) (1)
Leukemia/lymphoma development in IL-15-deficient TCR-transgenic mice (2015) (1)
Role and Molecular Biology of the Interleukin–2-Interleukin-2 Receptor System in Health and Disease (1986) (1)
Renal Regulation of Serum Protein Metabolism (1974) (1)
Corrigendum to “Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration” [J. Autoimmun. 21 (2004) 283–293] (2004) (1)
Phase I trial of recombinant immunotoxin anti-Tac -PE38 in patients with hematologic malignancies (1998) (1)
Protein-losing enteropathy in malignancy. (1977) (1)
Erratum to: ‘Mutation of epigenetic regulators TET2 and MLL3 in patients with HTLV-I-induced acute adult T-cell leukemia’ (2016) (1)
Immunodeficiency Disease and Malignancy (2020) (1)
Development of Zenapax®: A Humanized Anti-Tac Antibody (2019) (1)
Monoclonal anti tac antibody a suitable carrier for immunotoxin therapy in adult t cell leukemia (1984) (1)
SUPPRESSION OF IMMUNOGLOBULIN SYNTHESIS IN VITRO BY PURIFIED ANTIBODY TO IgD (1976) (1)
Blockade of IL-2 and IL-15 Gamma Chain Receptor Signaling Decreases Leukemic Cell Viability in T-Cell Large Granular Lymphocyte Leukemia and Adult T-Cell Leukemia (2017) (1)
Organization of the human immune system. (1990) (1)
16 – Adult T-cell Leukemia: Prospects for Immunotherapy (1991) (1)
A gain-of-function CCR4 mutations in adult T-cell leukemia/lymphoma (ATL) enhance the chemotactic abilities and P13K/AKT activation (2014) (1)
Recent progress in B- and T-cell lymphomas. (1994) (1)
Disorders of Immunoglobulin Catabolism (1972) (1)
Co-expression of IL-15 and IL-15Rα on pancreatic β islet cells induced insulin dependent diabetes mellitus in mice (161.2) (2012) (1)
Epitope Blocking: Positive and Negative Effects on the Biodistribution of 125I‐Labeled Anti‐Tac Disulfide‐stabilized Fv Fragment of Two Antibodies against Different Epitopes of the Circulating Antigen (1998) (1)
Letter from the editor (2019) (1)
Disorders of the expression of the multichain IL-2 receptor in HTLV-I-associated adult T-cell leukemia. (1989) (1)
Triple combination of BET plus PI3K and NF-κB inhibitors exhibit synergistic activity in adult T-cell leukemia/lymphoma (2022) (1)
Targeting the HTLV-I-Regulated BATF3/IRF4 Transcriptional Network in Adult T-Cell Leukemia/Lymphoma (2017) (1)
Genetically engineered monoclonal antibodies armed with radionuclides. (1993) (1)
The interleukin 2 receptor (IL-2R): The IL-2R a subunit alters the function of the IL-2R f8 subunit to enhance IL-2 binding and signaling by mechanisms that do not require binding of IL-2 to IL-2R a subunit (1)
90 Y-Daclizumab (Anti-CD25), High-Dose Carmustine, Etoposide, Cytarabine, and Melphalan Chemotherapy and Autologous Hematopoietic Stem Cell Transplant Yielded Sustained Complete Remissions in 4 Patients with Recurrent Hodgkin’s Lymphoma (2020) (1)
The proportion of TA, TG, and TM cells in various immunodeficiency and autoimmune disorders. (1983) (1)
T cell disorders in primary immunodeficiency diseases (1978) (1)
mechanism proliferation of primary adult T-cell leukemia cells by a paracrine Induction of the IL-9 gene by HTLV-I Tax stimulates the spontaneous (2013) (0)
Adenoviral Mediated IL-15 and IL-15R alpha Immunotherapy of a Murine Breast Cancer (2009) (0)
I-Mediated Activation of the IL-15 Receptor Human T Cell Lymphotropic Virus Type IFN Regulatory Factor 4 Participates in the Waldmann and Nazli Azimi (2002) (0)
131 Cytokine responses of naı¨ve T-cells requires special permission by accessory cells (2008) (0)
Serum proteins and the gastrointestinal tract. (1965) (0)
Subject Index, Vol. 3, 1984 (1984) (0)
HUMAN IMMUNOGLOBULIN GENES: THE ONTOGENY OF SOMATIC REARRANGEMENTS (1981) (0)
SURVIVAL OF CARDIAC XENOGRAFTS IN RHESUS MONKEYS. REPLIES (1991) (0)
Graft-versus-Host-Like Disease T Cells in an Experimental Mouse Model of CD 8 Determining the Activity of Autoreactive IL-15 Serves as a Costimulator in Waldmann and (2008) (0)
L-chain catabolism in mice with experimental fanconi syndrome produced by the renal tubular toxin, maleic acid. Abstr. (1969) (0)
Abstract LB-A06: Pipeline for High Throughput Analysis of Exosomes in Clinical Biofluids (2018) (0)
10 – IMMUNOLOGY—BASIC AND CLINICAL (1984) (0)
The role of the multichain IL-2 receptor complex in the control of normal and malignant T-cell proliferation. (1988) (0)
Clinical immunology: past, present and future challenges and prospects. (1991) (0)
Virus-I-Transformed T Cells Expression in Human T Cell Leukemia Regulation of IFN Regulatory Factor 4 (2002) (0)
ABNORMAL ACTIVATION OF STAT5 PROTEINS UPON IL-4 TRIGGERING OF ATLL CELLS (1999) (0)
Molecular Mechanism of IL-15 Gene Regulation in HTLV-I Infected Cells: Role of NF-κB and IRF-1 (1999) (0)
Immunotherapy targeting IL-2 and IL-15 cytokine receptors (2017) (0)
Responses on IL-15 Restricted − Selective Dependence of H 2M 3 (2012) (0)
ID: 238: IL-15 markedly augmented the number of circulating NK cells and enhanced ADCC mediated by tumor-directed monoclonal antibodies (2015) (0)
134 Accessory Cells Enable Cytokine Response of Naïve T Cells Through Cellular Contact Without Antigen (2007) (0)
CD8 Responses on IL-15 Restricted - Selective Dependence of H2-M3 (2012) (0)
Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocytic Leukemia (2019) (0)
Miceagainst Established T Cell Lymphomas in Effective Cytotoxicity of Dendritic Cells (2021) (0)
Abstract 3936: Frequent gain-of-function CCR4 mutations in adult T-cell leukemia/lymphoma (ATLL) (2015) (0)
p53-dependent senescence Persistent inhibition of telomerase reprograms adult T-cell leukemia to (2013) (0)
p53 STABILIZATION AND FUNCTIONAL IMPAIRMENT AND FREQUENT DELETION OF p161NK IN UNCULTURED ATLL CELLS (1999) (0)
Tricuspid regurgitation, a newly recognized cause of protein-losing gastroenteropathy, lymphocytopenia and an immunologic deficiency state (1967) (0)
A methodological approach for the study of protein synthesis by cell cultures in vitro. (1983) (0)
Antibody therapy (SY5-2) Chairpersons: Norihiro Nishimoto, Jeffrey V. Ravetch (2010) (0)
Phase I/II study of Yttrium-90 labeled humanized anti-Tac (HAT) monoclonal antibody and calcium DTPA in adult T-cell leukemia/lymphoma (ATL) (2006) (0)
The Molecular Biology of the Multisubunit Interleukin-2 Receptor (1988) (0)
Disorders of suppressor mediators associated with immunodeficiency and autoimmunity (1976) (0)
Pheochromocytoma: Current Concepts of Diagnosis and Treatment (2020) (0)
Functional and cellular imaging of acute renal failure in the mouse or rat model using gadolinium- and iron-based macromolecular MRI contrast agents (2005) (0)
Increased expression of IL-15 and IL-15Ra in the islets of patients with T1D (CCR3P.217) (2014) (0)
and Their Receptors in T Lymphocytes IL-15 Induces the Expression of Chemokines (1999) (0)
Inter leu ki n -2, Inter I eu ki n -1 5, and Their Receptors (1998) (0)
IL-21 e Driven Neoplasms in SJL Mice Mimic Some Key Features of Human Angioimmunoblastic T-Cell Lymphoma (2015) (0)
8 – Disorders of IL-2 Receptor Expression in HTLV-IAssociated Adult T Cell Leukemia (1989) (0)
PL3-1 IL-15 for the treatment of metastatic malignant melanoma and metastatic renal cell cancer (2010) (0)
Anti-IL-2 receptor antibodies as models for cancer therapy (2007) (0)
Clinical trial of a humanized monoclonal anti-IL15Rβ (CD122), in HTLV-1 associated myelopathy/ tropical spastic paraparesis (HAM/TSP) (2014) (0)
Molecular cloning of cDNA for the human interleukin-2 receptor. (1985) (0)
[Staphylococcus epidermidis infective endocarditis after mitral surgery, successfully treated with aspirin and antibiotics: a case report]. (2000) (0)
NK cells protect TCR-transgenic mice from developing fetal leukemia (2014) (0)
nonhuman primates Transient and persistent effects of IL-15 on lymphocyte homeostasis in (2011) (0)
Abstract 1596: Phase I trial of recombinant human Interleukin 15 (rhIL-15) administered as continuous intravenous infusion (CIV) for 10 days (240 hours) in patients with refractory metastatic cancers (2017) (0)
Monoclonal antibody therapy of T cell lymphoma: single agent trials of anti-CD2 (Siplizumab) and anti-CD4 (Humax-CD4) (2009) (0)
Accessory cells precondition naïve T cells and regulatory T cells for cytokine-mediated proliferation (2023) (0)
Effective Cytotoxicity of Dendritic Cells (2021) (0)
67 The Drug CP690550 Inhibits the JAK3/STAT5 Pathway In Vitro and In Vivo (2007) (0)
Immunoglobulin E in Immunologic Deficiency Diseases (1972) (0)
IL-15 Expands Unconventional CD8 (2008) (0)
Pretargeting radioimmunotherapy of a murine model of adult T cell leukemia ( ATL ) with the alpha emitting radionuclide , Bi-213 (2002) (0)
Comparison of glycolated 99mTc-MAG3-labeled F(ab')2 and Fab on tumor and kidney uptake (1999) (0)
Cytokine Receptor Directed Therapy with Genetically Engineered Monoclonal Antibodies Armed with Radionuclides (1993) (0)
REPLY TO SOCHA AND MOOR‐JANKOWSKI (1991) (0)
Erratum to: ‘Mutation of epigenetic regulators TET2 and MLL3 in patients with HTLV-I-induced acute adult T-cell leukemia’ (2016) (0)
Neoplastic Disease Levels in Patients with Serum Immunoglobulin E and (2006) (0)
This information is current as Independent of CD4 T Cell Help Longevity of CD8 T Cells That Are Partially Plasmid Results in Enhanced Function and Coimmunization with an Optimized IL-15 (2013) (0)
LB1517 Clinical effects of BNZ-1, a selective inhibitor of IL-2/IL-9/IL15 in development for alopecia areata (2018) (0)
Protein-losing Enterolmthy and Kinetic Studies of Plasnm Protein Metabolism (1972) (0)
Expressing the Human T Cell Growth Factor Receptor (1984) (0)
Genome-Wide CRISPR Library Screening Identifies CDK6 As Genetic Vulnerability in Adult T-Cell Leukemia/Lymphoma (2019) (0)
Methode de traitement de l'uveite active (2005) (0)
Molecular Genetic Analysis of Human Lymphoid Neoplasms (2020) (0)
Human T-Cell Lymphotropic Virus Type I\p=m-\AssociatedAdult T-Cell Leukemia (2017) (0)
Overcoming CD4 deficiency to induce long-lived memory CD8+ CTL (2006) (0)
Daclizumabof its Use in the Management of Organ Transplantation (2001) (0)
Comparison of Macromolecular Contrast Agents for Dynamic Micromagnetic Resonance Lymphangiography (2005) (0)
Contents, Vol. 3, 1984 (1984) (0)
Interleukin-15 (IL-5) in Combination with Avelumab in Relapsed/Refractory Mature T-Cell Malignancies (2019) (0)
The Interleukin-2 Receptor : A Target for Monoclonal Ant ibody Treatment of Human T-Cell Lymphotrophic Virus I-Induced Adult T-Cell Leukemia (2017) (0)
leukemia/lymphoma FERM domain mutations induce gain of function in JAK3 in adult T-cell (2011) (0)
Significance of in vivo and in vitro metabolic studies of tumour-produced proteins (1984) (0)
Making discoveries in immunology (2019) (0)
Abstract 2526: CP690550 inhibits interleukin-2 (IL-2), IL-9 and IL-15 mediated JAK3 activation and proliferation of T cells obtained from patients with HTLV-1-associated adult T cell leukemia (ATL) and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) (2010) (0)
The maturation of a pre-B cell to an immunoglobulin (Ig)-bearing B cell requires an effective recombination of a light chain variable (VL) (2003) (0)
Highlights of the 46th Annual Meeting of the American Academy of Allergy and Immunology: Post-Graduate Sessions (1990) (0)
A T‐cell line with an unusual phenotype (1989) (0)
IL-15 (cid:1) IL-15R (cid:1) -mediated avidity maturation of memory CD8 (cid:2) T cells (2004) (0)
Failure in Patients with Advanced Malignancy A Pilot Study of CTLA-4 Blockade after Cancer Vaccine (2007) (0)
The g5R (D250) Gene of African Swine Fever Virus Encodes a Nudix Hydrolase That Preferentially Degrades Diphosphoinositol Polyphosphates (2002) (0)
Inside Back Cover: Distinct Spatial Relationship of the Interleukin‐9 Receptor with Interleukin‐2 Receptor and Major Histocompatibility Complex Glycoproteins in Human T Lymphoma Cells (ChemPhysChem 18/2014) (2014) (0)
Molecular Cloning and Expression of cDNAS Encoding the Human Interleukin-2 Receptor (1985) (0)
IMMUNOLOGICAL DISORDERS IN PATIENTS WITH INTESTINAL LYMPHANGIECTASIA (1969) (0)
Germinal epimutation of Fragile Histidine Triad (FHIT) gene is associated with progression to acute and chronic adult T-cell leukemia diseases (2021) (0)
Immune Disorders with New Features for Immunotherapy in Malignant and Anti-TacH , a Humanized Antibody to the Interleukin 2 Receptor Updated (2006) (0)
The implications of IL-15 trans-presentation on the immune response. (2022) (0)
HUMAN T-CELL LYMPHOTROPIC VIRUS-I TAX PROTEIN TRANSACTIVATES IL-2 AND IL-15 GENE TRANSCRIPTION: PATHOGENIC IMPLICATIONS AND RATIONALE FOR IMMUNOTHERAPY. (1999) (0)
Interleukin-15 and Its Receptor Enhance Antitumor Activity Following a Genetically Modified Dendritic Cell Vaccine (2008) (0)
A defect in antigen-specific antibody production due to a lack of T helper cells in a patient with ataxia-telangiectasia. (1981) (0)
Antitumor Activity Of Recombinant Inumunotoxin Anti-tac(fv)-pe38 (lmb-2) In Patients With Hematologic Malignancies (1999) (0)
Mutation of epigenetic regulators TET2 and MLL3 in patients with HTLV-I-induced acute adult T-cell leukemia (2016) (0)
LYMPHOID NEOPLASIA Markedly additive antitumor activity with the combination of a selective survivin suppressant YM155 and alemtuzumab in adult T-cell leukemia (2013) (0)
Daclizumab for Active, Non-Infectious, Sight-Threatening Uveitis: A Phase II Pilot Study (2008) (0)
Study of two stabilizers to maintain the radiochemical integrity of Y-90-CHX-A-HAT (2009) (0)
Mice IL-15 Confer Sterile Cross-Clade Protection Avian Influenza Vaccines Adjuvanted with Vaccinia Virus-Based Multivalent H 5 N 1 Perera (2009) (0)
The metabolism branch: an exemplar of patient-oriented research. (1995) (0)
Disorders of immunoglobulin metabolism. (1969) (0)
CITN11-02 phase I trial of subcutaneous recombinant human IL-15 (rhIL-15) is associated with expansion of circulating CD56+ NK cells and CD8+ T cells (2016) (0)
The Interleukin-2 Receptor : A Target for Monoclonal Antibody Treatment of Human Tc e l l Lymphotrophic Virus I-Induced Adult Tc e l l Leukemia (2003) (0)
Polycythemia in rats with adrenal cortical carcinoma transplants. (1966) (0)
CITN-06: a Phase I/expansion trial of alt-803, an IL-15 superagonist, in patients with advanced melanoma (2014) (0)
Molecular Analysis of the Human Interleukin-2 Receptor (1985) (0)
Interleukin-2 Receptors (1985) (0)
TheSharedandContrastingRolesof IL2and IL15 in the Life and Death of Normal and Neoplastic Lymphocytes: Implications for Cancer Therapy (2015) (0)
Metabolism of Immunoglobulins (Part 2 of 3) (1969) (0)
Abstract LB-015: Phase I trial of recombinant human interleukin 15 (rhIL-15) in combination with nivolumab and ipilimumab in refractory cancers (2019) (0)
TheMechanism ofAppearance ofImmunoglobulin A in Nasal Secretions inMan (1967) (0)
Beta-catenin signaling regulates acute adult T-cell leukemia/lymphoma (2007) (0)
features (see comments) clinical of a subset of patients with distinctive immunophenotypic and Characterization of common variable immunodeficiency: identification (2011) (0)

This paper list is powered by the following services:

Other Resources About Thomas A. Waldmann

en.wikipedia.org

What Schools Are Affiliated With Thomas A. Waldmann?

Thomas A. Waldmann is affiliated with the following schools:

Thomas A. Waldmann's Academic­Influence.com Rankings